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Abstract
Tumour infiltrating lymphocytes influence colorectal cancer (CRC) progression. 
However, lymphocyte infiltration comes in different flavours and evidence has 
been provided that the spatial distribution of immune cells within the tumour 
tissue is an important immunological feature. The aim of this thesis was to 
investigate how the dual localization of tumour infiltrating lymphocytes (TILs) can 
affect their function in the tumour microenvironment. The project started with the 
analysis of the CD3 compartment, as CD3+ T cell infiltration (CD3-TILs) is a 
recognized positive prognostic factor for CRC patients. Results here presented 
show that CD3+ tumour-infiltrating lymphocytes are present both interspersed in 
the tumour tissue or scattered throughout the stroma (CD3-TILs) and also 
aggregated in lymphoid structures showing features of tertiary lymphoid tissue 
(CD3-TLT). Tumour-associated TLT had a peculiar compartmentalization, with 
CD3+ T cells and CD20+ B lymphocytes holding complementary positions and with 
distinct types of dendritic cell populations among them. The presence of HEVs 
(High Endothelial Venules) suggests a role for TLT in T cell recruitment at the 
tumour site. To test this hypothesis in human cancer, I performed a whole tissue 
analysis of the CD3+ infiltrate on CRC sections and found a positive correlation 
between CD3-TIL and CD3-TLT densities. I further confirmed the hypothesis in 
vivo in a murine model of colitis-associated cancer (AOM/DSS). AOM/DSS treated 
mice had expanded TLT compared to control mice. Intravenously injected GFP+ 
splenocytes localised in TLT of tumour-bearing mice more than in control mice. I 
then investigated the clinical significance of CD3-TLT in relationship with CD3- 
TILs in a cohort of 351 CRC patients. In patients with node-negative (without 
lymph node metastasis, stage II) CRC, a high density of CD3-TLT and CD3-TILs 
associated to a better prognosis, while in patients with node-positive (presence of 
lymph node metastasis, stage III) CRC, TLT and TIL density were irrelevant in 
predicting patient prognosis, thus behaving as biomarkers only for early stage CRC 
patients.
In the second part of my thesis, I analysed the distribution of B cells in colorectal 
cancer and their possible contribution to disease progression. Despite still
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controversial, increasing evidence that B cells play a role in cancer progression has 
been provided, bringing up the hypothesis that also B-cell responses should be 
considered as targets of immunotherapeutic approaches. Similarly to CD3+ cells, I 
showed that, both in human and in preclinical models of CRC, B cells display a dual 
geographical distribution, either within tertiary lymphoid tissue (CD20-TLT] or 
dispersed at the tumour invasive margin (CD20-TILs). Therefore, I evaluated the 
role of B cells according to their localization in the microenvironment. I found that 
CD20-TLT associated to better prognosis, while CD20-TILs did not. Interestingly, 
CD20-TLT correlated with CD20-TILs only among patients who experienced 
cancer recurrence. This result suggests that, when located within a lymphoid site, 
B cells might have a protective anti-tumour function, participating in an anti­
tumour immune response. Conversely, the distribution of B cells scattered in the 
microenvironment is likely to reflect a non-specific pro-tumour inflammatory 
reaction. To confirm the hypothesis in vivo and attempt to dissect the dual function 
of B cells, I took advantage of two CRC preclinical models in which B cells present a 
distinct geographical distribution in the tumour microenvironment. In the first 
model, B cells mainly localise within TLT, while in the second one B cells diffusely 
infiltrate the mucosa, without forming aggregates. I found that in a model in which 
B cells localize primarily within TLT, the genetic deficiency of B cells significantly 
increased tumour formation, suggesting that B cells within TLT might exert an 
important anti-tumour function. In contrast, in a model in which B cells only 
localize within the tissue, genetic deficiency of B cells reduces tumour growth, 
suggesting that infiltrating B-TILs might have a pro-tumour role.
Therefore, the occurrence of TLT is associated with lymphocyte infiltration in CRC, 
contributing to recruitment of CD3-TILs. TLT and TILs work together to set up an 
anti-tumour immune response in patients with low-risk early-stage colorectal 
cancer. Thus, TLT represents a novel prognostic biomarker for CRC. As to the B cell 
compartment, their differential distribution in the tumour site corresponds to 
distinct prognostic functions. This evidence suggests that the design of novel 
immunotherapeutic drugs depleting B cells should take into account their ability to 
selectively targeting CD20-TILs but not C20-TLT.
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INTRODUCTION
COLORECTAL
CANCER
8
C o lo rec ta l c a n c e r
Epidemiology
Colorectal cancer [CRC] is the third most commonly diagnosed cancer and 
one of the leading causes of cancer mortality in the world. It accounts for over 9% 
of all cancer incidence [1, 2]. The World Health Organization (WHO) evaluates that 
approximately one million new cases occur worldwide every year [3]. CRC 
corresponds to the 9.4% of all incident cancers in men and 10.1% in women. It is 
not uniformly distributed throughout the world [1, 4], as it is more frequent in 
industrialized than developing countries. Therefore, every population has its own 
incidence rate of colorectal cancer, which changes overtime. Differently from 
Northern and Western Europe, the incidence of CRC in the United States is 
dwindling, a trend that is attributed to screening programs that may have 
improved the detection of precancerous lesions [5]. In all the other places, 
however, the incidence is increasing rapidly, in particular in those countries where 
the transition from a low-income to a high-income economy has recently taken 
place, such as Japan, Singapore and Eastern European countries [1, 6]. Worldwide 
differences in the outcome are related to diet, genetic factors, population life span, 
socio-economic factors, access to therapies and quality of the latest [3].
Risk factors and causes
The possibility of developing colorectal cancer rises gradually from the age 
of 40, increasing rapidly from the age of 50. More than 90% of colorectal cancer 
patients are older than 50 years old [4].
Colorectal cancer develops from pre-neoplastic lesions, which are polyps of the 
colorectum, also known as tubular or villous adenomas [5]. Approximately 95% of 
sporadic CRC derives from these adenomas [4]. Therefore, adenomas increase the 
risk of an individual to develop cancer [7]. Adenomas need 5-10 years prior to
malignant transformation; thus, early detection and removal of adenomas reduces 
cancer risk [8].
Risk factors can be divided in modifiable, usually environmental agents 
such as diet, sedentary life-style, obesity and smoking, and non-modifiable. The 
latest include age and hereditary factors, both uncontrollable by an individual. 
Among others, persistent inflammation of the intestine is emerging as an 
important risk factor. Inflammatory Bowel Disease (IBD) is a term that includes 
Ulcerative Colitis and Crohn's disease. In the first one, the lining of the large 
intestine is the target of chronic inflammation; in the second one, inflammation 
takes place in the lining and in the wall of the large and/or small intestine. Both 
these conditions predispose to development of colorectal cancer. The relative risk 
of CRC in patients with IBD has been estimated between 4- to 20- fold [6].
In approximately 75% of patients, CRC is a sporadic disease [9], where 
genetic and environmental factors (modifiable factors) are important 
determinants of the disease (Table 1). In these cases, patients don't have a family 
history of CRC or a predisposing disease. The remaining 25% of patients presents a 
family history of CRC or adenomatous polyps that suggests a hereditary 
contribution, common exposure to environmental factors among family members, 
or a combination of both [3]. In only the 5-6% of all CRC cases, genetic mutations 
have been associated to inherited cancer risk and a defined hereditary cancer 
syndrome develops [6]. There are two main syndromes: hereditary non polyposis 
colorectal cancer (HNPCC) and familiar adenomatous polyposis (FAP) [10]. Genetic 
mutations responsible for these inherited forms of CRC have been identified. 
HNPCC patients have mutations in genes involved in the DNA repair pathway, 
MLH1 (human MutL homolog 1) and MSH2 (human MutS homolog 2) genes. FAP 
syndrome is due to mutations in the tumour suppressor gene APC (Adenomatous 
Polyposis Coli). HNPCC accounts for 2 to 6% of colorectal cancer; FAP accounts for 
less than 1% [9].
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Colorectal cancer development is due to the accumulation of genetic 
alterations (gene mutations, gene amplification, and so on) and epigenetic 
alterations (aberrant DNA methylation, chromatin modifications, and so on). The 
earliest steps in the tumorigenesis include genomic instability and, as its 
consequence, gene alterations. Both events contribute to the transformation from 
normal colonic epithelium to colon adenocarcinoma, combining alterations in 
tumour suppressor genes and oncogenes that facilitate cell transformation and 
tumour progression.
There are two major pathways involved in CRC: the chromosomal instability 
pathway (CIN) and the microsatellite instability pathway (MSI). Recently, it has 
been demonstrated that there are other routes, including the serrated and 
epigenetic pathway. Moreover, all these pathways may establish a cross-talk, 
highlighting the variety of genes involved in CRC development.
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Risk factors and causes
Sporadic colorectal cancer (88-94%)
Older age 
Male sex 
Cholecystectomy 
Ureterocolic anastom osis
Hormonal factors: nulliparity, late age a t  first pregnancy, early m enopause  
Environmental factors
Diet rich in m ea t  and fat, and poor in fibre, folate and calcium
Sedentarity  lifestyle
Obesity
Diabetes mellitus 
Smoking
Previous irradiation
Occupational hazards (eg, asbes tos  exposure)
High alcohol intake
Personal history o f sopradic tumours 
History of colorectal polyps 
History of colorectal cancer
History of small bowel, endom etria l ,  b reas t  or  ovarian cancer 
Familial colorectal cancer (20%)
First or  scond deg ree  relatives with this cancer, criteria for 
hereditary  colorectal cancer no t fulfilled:
- One affected first-degree relative increases risk 2-3 fold
- Two or m ore  affected first-degree relatives increase risk 4-25 fold
- Index case <45 years increases risk 3-9 fold
- Familial history of colorectal ad en o m a  increases risk 2-fold
Colorectal cancer in inflammatory bowel disease (1-2%)
Ulcerative colitis 
Chron's  d isease
Hereditary colorectal cancer (5-10%)
Polyposis-syndromes: fam ilial adenomatous polyposis (FAP), Gardner 's  syndrom e, 
Turcot's  syndrom e, a t te n u a te d  a d en o m a to u s  polyposis coli, flat a d en o m a  syndrom e 
Hereditary non-polyposis colorectal cancer (HNPCC)
H am artom atous  polyposis syndrom es
Table 1. Summary of CRC risk factors and causes. Adapted from Weitz, 2005 [3]
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AJCC (TNM) Staging System o f colorectal cancer
As mentioned above, a significant heterogeneity is present in the history of 
individual colorectal tumours. However, based on a specific staging system, broad 
generalizations can be made concerning the diagnosis and treatment approach of 
CRC [11]. The AJCC/UICC TNM classification is the most common classification 
system for the staging and prognostication of cancer; it summarizes data on 
tumour burden [T], presence of cancer cells in draining and regional LN (N) and 
evidence of metastases (M). However, it has emerged that patients within the same 
TNM stage may have a range of clinical outcomes, suggesting that this system 
should be improved [12].
According to the AJCC (TNM) system, CRC ranges from Stage I to stage IV. Stage I 
includes primary tumours that invade the sub mucosa (Tl) and those invading the 
muscularis propria (T2), without regional lymph node metastasis (NO) and distant 
metastasis (MO). Stage II consists of stage IIA, including tumours invading through 
the muscolaris propria into sub serosa (T3), and stage IIB, including tumours that 
directly invade other organs or structures (T4). Stage II does not include nodal or 
distant metastasis. Stage III consists of stage IIIA, including T l and T2 with nodal 
metastasis, and stage IIIB, including T3 and T4 with nodal metastasis, stage IIIC, 
including only nodal metastasis with any T. Stage IV shows distant metastasis 
without any primary tumours or any nodal metastasis. Another factor that can 
affect the survival expectation is cancer grade. Table 2 summarizes the 
characteristics of colorectal cancer staging in this system.
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T-Primary tumour
TX Primary tumour cannot be assessed
TO No evidence of primary tumour
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria
Tl Tumour invades submucosa
T2 Tumour invades muscularis propria
T3 Tumour invades through the muscularis propria into subserosa or into non-peritonealised pericolic or 
perirectal tissues
T4 Tumour directly invades other organs or structures and/or perforates visceral peritoneum
N -  Regional lymph node
NX Regional lymph nodes cannot be assessed
NO No regional lymph node metastasis
N1 Metastasis in 1 to 3 regional lymph nodes
N2 Metastasis in 4 or more regional lymph nodes
M-Di stant metastasis
MX Distant metastasis cannot be assessed
MO No distant metastasis
Ml Distant metastasis
Stage T N M
Stage I Tl, T2 NO MO
Stage IIA T3 NO MO
Stage IIB T4 NO MO
Stage IIIA Tl, T2 N1 MO
Stage IIIB T3,T4 N1 MO
Stage IIIC AnyT N2 MO
Stage IV AnyT AnyN Ml
Table 2. TNM staging system for colorectal cancer.
Tumour staging has been by far the most important prognostic predictor of clinical 
outcome for patients with CRC [13]. Colorectal cancer survival is strictly related to 
the stage of the disease at diagnosis, and usually ranges from a 90% 5-year 
survival rate for cancers detected at localized stage; 70% for regional; to 10% for 
patients diagnosed for distant metastatic cancer [4]. In general, the earlier the 
stage at diagnosis, the higher the chance of survival [3]. Mortality related to 
colorectal cancer is nearly half that of the incidence [3].
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Predictive/prognostic markers and therapeutic treatm ents
Understanding the molecular basis of colorectal cancer has provided tools 
for genetic testing for high-risk familial forms of the disease. Moreover, drug 
therapies are selectively allocated to patients thanks to predictive markers, which 
guide the clinicians, by providing an estimation on how the individual will respond 
to that therapy. In addition, molecular diagnosis allows a non-invasive detection of 
early cancers.
Studies aimed at deepen in the molecular aspects of CRC pathogenesis 
identified biological pathways that may help the development of new therapeutic 
agents [14]. Until now, the only molecule targeted by clinical therapies is the 
epidermal growth factor receptor (EGFR) [15-18]. However, several genomic 
markers are efficient tools for prognosis. For instance, germ-line mutations in 
tumour-suppressor genes, such as APC, MLH1, MSH2, indicate a high-risk of 
developing colorectal cancer and are also associated to CRC [19-22].
Other genetic alterations can be considered as prognostic markers. For 
instance, loss of heterozygosis at chromosome 18q is associated with poor survival 
in stage II and stage III CRC [21]. MMR deficiency in sporadic CRC usually is 
associated with a favourable prognosis and a lower chance to develop distant 
metastasis [23].
Screening programs, including faecal occult-blood test, flexible 
sigmoidoscopy, double-contrast barium enema and colonoscopy, have 
considerably reduced CRC mortality [24]. Colonoscopy is the gold standard for 
diagnosis of CRC, together with abdominal ultrasound and chest radiography [3]. 
for patients For patient categories with a personal or familial history of colorectal 
adenomas or colorectal cancer [FAP, HNPCC or IBD) specific surveillance 
guidelines exist [25].
For early-stage CRC that have not spread to distant sites surgical 
intervention is the first line therapy. Up to date, surgical techniques have been 
improved a lot [26]. Chemotherapy may also be used after surgery (adjuvant 
chemotherapy) if cancer has a higher risk of recurrence. For stage III tumours,
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where cancer has spread to nearby lymph nodes, the standard treatment includes 
surgery followed by adjuvant chemotherapy. For metastatic patients (Stage IV], in 
which cancer has spread from the colon to distant organs and tissues, 
chemotherapy is the first line care: FOLFOX (5-Fluorouracil (5-FU], leucovirin, and 
oxaliplatin] or FOLFIRI (5-FU, leucovirin, and irinotecan) are the most commonly 
used [27].
Immunotherapy includes therapeutic strategies that harness the immune 
system to eradicate tumours. CRC, as many other tumours, exerts multiple 
strategies to suppress and evade the immune system, thus representing a clinical 
setting in which immunotherapeutic strategies could provide clinical benefit. 
Among other immunotherapeutic strategies, monoclonal antibodies (mAbs] have 
shown their clinical effectiveness for decades. Antibodies such as Bevacizumab, 
directed against VEGF, [28, 29] and cetuximab or panitumumab, both directed 
against EGFR, have been approved and are currently used for the treatment of CRC 
in the USA. Many clinical trials are currently testing other mAbs targeting 
pathways that should induce tumour death, for instance by disruption of vital 
signalling pathways. Another class of antibodies includes the so called "checkpoint 
inhibitors", mAbs that target the inhibitory immune receptors CTLA-4, 
programmed cell death-1 (PD-1], and PD-1 ligand (PD-L1). In CRC, preliminary 
studies have shown the limited efficacy of these kind of antibodies, when used as 
single agents [30, 31]. The poor efficacy of current immunotherapies in CRC 
revealed the relatively resistant nature of CRC to immune-based strategies. 
However, combination of conventional chemotherapy or radiation with 
immunotherapy might be effective in the clinic [32].
Due to the heterogeneity of CRC, patient response to therapies is very 
inconstant, being the main impediment for the optimization of therapeutic 
strategies. In order to help the development of new therapeutic treatments, an 
important aim is to identify biomarkers to predict treatment response [33]. Among 
emerging biomarkers of prognosis and response to treatment, immune mediators 
appear to occupy a key position, encouraging the research of immune based 
therapeutic approaches [34, 35].
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The IMMUNE 
INFILTRATE in 
COLORECTAL 
CANCER
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Cancer and inflammation
Cancer progression is a multi-step process, which involves several events, 
including, among the earliest, genomic instability and epigenetic alterations. As a 
consequence of these events, tumour cells acquire specific features that have been 
summarized by Hanahan and Weinberg in the six hallmarks of cancer [36]. The 
first signature of malignant cells highlight intrinsic characteristics of these cells, 
such as sustaining proliferative signalling or resisting cell death, regardless of what 
happens in the neighbourhood. Lately, tumour microenvironment has received 
more attention and its role in the evolution of the disease has been recognized of 
primary importance. Tumorigenic mechanisms that depend on the interaction 
between malignant cells and the tumour microenvironment have been included in 
the emerging hallmarks [37, 38]. Among others, the role of inflammatory 
mediators in cancer has been recognized, so that inflammation has been integrated 
as the seventh hallmark of cancer [Figure 1).
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Figure 1. The seven hallm arks of cancer. This picture represents the peculiar 
and complementary capabilities that allow tumour growth and dissemination. 
Adapted from Colotta, 2009 [39]
Chronic inflammation is likely to be one of the primary causes of several human 
cancers including colorectal cancer. CRC represents a paradigm of the link between 
cancer and inflammation. Epidemiologic and clinical studies indicate that patients 
affected by IBDs (Ulcerative colitis or Crohn's disease) have an increased risk of 
developing neoplasia, with an increased incidence rate of 2.75 and 2.64 of CRC in 
patients with ulcerative colitis and Crohn's disease, respectively [40-43]. The 
mechanisms involved in this process are still poorly understood.
Recently, immune cells and their mediators have been shown to have a 
pivotal role in triggering colitis-associated colorectal cancer (CAC) development 
through the induction of DNA alterations in intestinal epithelial cells. Indeed, 
accumulation of activated immune cells, such as neutrophils, macrophages and 
dendritic cells is combined with the release of reactive oxygen and nitrogen 
reactive species, which have been demonstrated to induce genomic mutations [44]. 
In addition, DNA methylation and histone modification are likely to be linked to 
chronic inflammation [39, 45, 46]. All these events lead to an altered expression of 
oncogene such as p53, APC, KRAS [47]. After the genomic events, dysplastic cells 
become target of cell-derived growth factors and cytokines, which promote 
tumour growth. From the other side, the immune system has been demonstrated 
to act as negative regulator of tumour growth, controlling dysplastic cells. This 
happens till a change in the equilibrium selects dysplastic cell clones capable of 
growing, thanks to growth factors and pro-inflammatory cytokines; at this point, 
the immune system becomes a cancer promoter [40].
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Although IBDs are chronic inflammatory and immune-mediated diseases, 
CAC and other types of CRC not directly related to inflammation share some 
similarities; for instance, the progressive sequence of tumour development from 
the aberrant crypt foci to carcinomas is similar in both. Even genetic and some of 
the main signalling pathways, such as Wnt, K-Ras, p53, MMR proteins, are 
common. Obviously, CAC has its specific characteristics, among which there are 
some pathogenic mechanisms, comprising, first of all, chronic inflammation and 
injuiy-dysplasia carcinoma; the latest does not develop from a prior formed 
adenoma. However, the presence of an inflammatory infiltrate and molecules 
appears even in CRC not directly related to IBDs [48].
Im m une resp on se to tum ours
Tumour context is a multifaceted and dynamic environment, where stromal 
cells, fibroblasts, endothelial cells, innate cells and lymphocytes interact each other 
and with tumour cells. The balance of these close interactions results in tumour 
growth and spread. Therefore, the cross-talk between tumour cells and their 
microenvironment is extensively considered critical for cancer progression and 
prognosis, with a special reference to immune infiltrating cells [49].
It has been well established that a leukocyte infiltrate is present in most
tumours. It has been generally accepted that the immune system can protect the
host against tumour progression through mechanisms of immunosurveillance [50].
Some of the main mechanisms whereby the immune system limits cancer include:
the prevention of an inflammatory environment that provide a suitable milieu for
tumour development by the elimination of pathogens and resolution of
inflammation; recognizing the so called "tumour antigens", proteins expressed on
the tumour cell surface that make them different from their normal counterpart,
thus eliminating tumour cells [51]. However, depending on the type of infiltrating
immune cells, the effect on tumour progression is different and, according to the
cancer type, they can inhibit or enhance tumour growth [52]. The "seven
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hallmarks" of cancer have been recently modified by Hanahan and Weinberg, 
including "avoiding immune destruction" as emerging hallmark, in addition to CRI 
[38, 52].
The im m une infiltrate in hum an colorectal cancer
The heterogeneity of tumour immune infiltrate is due to the diversity of cell 
types and where these cells localize in the tumour tissue, both parameters 
changing according to the tumour type. All immune cell types may be present in a 
tumour; they can be localized in the core of the tumour, at the invasive margin or 
in tertiary lymphoid tissue (TLT). Macrophages, mast cells, granulocytes and 
myeloid-derived suppressor cells (MDSCs) are usually present within or 
surrounding tumour beds, both in the core and at the invasive front of the tumour. 
Tumour-infiltrating lymphocytes are localized in specific areas. NK cells have often 
a stromal localization that does not favour a direct interaction between NK and 
malignant cells. B cells can be observed both at the invasive margin of tumours and 
in tertiary lymphoid tissue (TLT) [53, 54]. T lymphocytes can be found at the 
invasive front and also within the tumour core and even in TLT.
In the colon, an immune infiltrate is already present in benign adenomas 
and it significantly increases in CRC tissues. Immune cells are localized both at the 
periphery and in the tumour stroma, occasionally invading cancer cell nests. Most 
represented leukocytes are T lymphocytes and macrophages, although some B 
cells, neutrophils, eosinophils, mast cells, NK cells and rare DCs can be found [55- 
59].
The prognostic value of the TNM staging system has been recently 
challenged [60]. One of the evidence that lead to review the reliability of the TNM 
has been that patients with poorly invading but node-positive CRC have a better 
prognosis than patients with deeper invading but node-negative CRC. As a
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complementary and integrative prognostic method, the quantitative assessment of 
the immune response has been proposed [61], as I will discuss later.
Tumour-infiltrating lymphocytes in CRC 
Overview on lymphocyte development and activation
The immune system consists of a wide range of distinct cell types: 
lymphocytes have a central role because they confer antigen-specificity and are 
therefore responsible for adaptive immune responses. In my thesis, I first focused 
on T lymphocytes, which have important regulatory and effector roles, and then on 
B lymphocytes, specialised cells that produce antibodies. [62]
Lymphocytes develop from stem cells in the bone marrow. All lymphocytes 
go through complex maturation stages during which they express antigen 
receptors and acquire functional and phenotypic features of mature cells. B 
lymphocytes mature in the bone marrow, while T lymphocytes migrate to and 
mature in the thymus. After cell maturation, they leave the bone marrow or the 
thymus, enter the blood stream, and reach secondary lymphoid organs. These 
mature cells are called naive lymphocytes. Naive B and T lymphocytes are mature 
cells that have not been stimulated by antigen to become differentiated 
lymphocytes. Upon antigen encounters, lymphocytes differentiate into activated 
cells that have functions in protective immune responses. Activated lymphocytes 
include CD4+ T helper cells, CD8 + cytotoxic T lymphocytes (CTL] and antibody- 
secreting B cells. Differentiated helper T cells provide help to B cells to proliferate 
and produce specific antibody and stimulate inflammation. Differentiated CTLs 
develop granules containing proteins that kill virus-infected and tumour cells. B 
lymphocytes differentiate into cells that actively synthesize and secrete antibodies. 
Some of the progeny of antigen-stimulated B and T lymphocytes differentiate into 
memory cells, whose function is to mediate rapid and enhanced responses to 
second or subsequent exposures to antigens. Memory cells may survive in a 
functionally quiescent or slowly cycling state form many years after the antigen is 
eliminated. [62]
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T cell population is usually identified by the marker CD3 that is expressed 
on the cell surface at all stages of T cell development. Most of B cells are 
characterised by the expression of CD20 marker.
Function and their prognostic relevance in CRC
As in melanoma [63] and in ovarian cancers [64], tumour-infiltrating 
lymphocytes (TILs) limit tumour growth and are associated with improved 
prognosis [65, 66] also in CRC [61]. Several studies confirmed that the presence of 
TILs, in particular intraepithelially, is beneficial for patient outcome, being 
associated with earlier tumour stage, decreased local recurrence rate after surgery 
and improved overall and disease-free survival, both in metastatic and non­
metastatic patients [66-68].
Galon et al. analysed TILs by gene expression profiling and 
immunohistochemistry; they looked at the type, density and localization of cells in 
a large cohort of CRC patients [61]. They demonstrated that the adaptive immune 
response favours patient survival and prevents tumour recurrence in both stage II 
and III patients. Moreover, they found a dominant cluster of genes involved in Thl 
immune responses that inversely correlated with tumour recurrence. Pages et al. 
investigated the role of TILs in early metastatic invasion, a process characterized 
by the presence of VELIPI (vascular emboli, lymphatic invasion and perineural 
invasion). They found that VELIPI-negative patients present a huge immune 
infiltrate, including effector memory T cells, and a strong Thl response, both 
evidence resulting in a prolonged survival [69].
Laghi and colleagues focused their attention on CD3+ TILs and they 
evaluated them at the invasive front of the tumour in stage II and III CRC patients 
[60]. According to the above studies, CD3+ TILs are associated with a lower risk of 
metachronous metastasis, thus predicting prolonged survival. Notably, this is true 
only in stage II patients (node-negative) and has no longer statistical significance 
in stage III patients (node-positive), i.e. tumours that have already spread to 
distant organs, raising the hypothesis that the immunesurveillance capability of 
CD3+ TILs is compromised in advanced stage tumours [60].
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Camus et al. with the expression "immune coordination" wanted to resume 
the concept of coordination of the intra-tumour immune response. They have 
demonstrated that the higher is the grade of coordination the better is the 
prognosis. A higher coordination is associated with a high percentage of tumour- 
infiltrating T cells. In patients with a low density of these cells, there is impairment 
in the immune coordination, thus a poorer prognosis [70]. Moreover, they have 
found a positive correlation between a high density of tumour-infiltrating T cells 
and late memory and cytotoxic phenotypes of CD8+ T cells and even with a strong 
Thl response. All these elements are crucial for the elimination of migrating 
malignant cells. As long as the equilibrium of the immune coordination at the 
primary tumour site is solid, metastasis can not occur. To sum up, tumour- 
infiltrating T cells have been clearly demonstrated to have a protective role in CRC.
Tumour-infiltrating B lymphocytes in CRC
While the role of T lymphocytes in cancer and their relationship with 
prognosis have been deeply assessed, the role of B cells in the tumour 
microenvironment and their impact on clinical outcome are still debated. Besides 
antibody-mediated effects, antibody-independent mechanisms such as antigen 
presentation, cytokine production, direct cytotoxicity and indirect effects through 
modulation of other immune cell types have been proposed to be of importance 
[71-74].
Studying autoimmune diseases through murine models has helped in 
identifying B regulatory cell (Breg] subsets with immune suppressive functions 
(Figure 2), including B cell subsets producing IL-10 and TGF-p, which can mediate 
the recruitment and expansion of T regulatory cells [72, 75]. Scientists are making 
many efforts in order to investigate whether similar immune suppressive B cell 
subsets migrate to the tumour and acquire an immune suppressive phenotype, 
potentially leading to the attenuation of the local anti-tumour immune response 
[76].
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Experimental evidence has shown that B cells have a dual role in cancer: on 
the one hand they can produce antibody or act as antigen-presenting cells (APCs), 
promoting the anti-tumour activity of tumour-infiltrating T cells [77-80]; on the 
other hand, the production of antibodies and cytokines can foster tumour 
development in a paracrine fashion [81, 82]. In particular, B cells play a key role in 
the maintenance of an immunosuppressive environment, modulating the 
polarization of the myeloid compartment in a pro-tumour direction. They exert 
this function by producing cytokines, such as IL-10 [72, 83] and PDL-1 [73], and 
antibodies that can form immunocomplexes, in turn activating the Fc gamma 
receptor on myeloid cells [84].
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Figure 2. Functional properties of B reg cells. Schematic representation of the 
main functional features of B reg cells. They produce suppressive cytokines, such 
as IL-10, TGF-|3 and IL-35, through which they suppress the differentiation of pro- 
inflammatory leukocytes, including IL-12-producing DCs, TNF-a producing 
monocytes, Thl7 cells, Thl cells, cytotoxic CD8+T cells. Moreover, B reg cells can 
stimulate the differentiation of immunosuppressive T cells, Foxp3 +T cells and Trl,
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and contribute in the maintenance of iNKT cells. Adapted from Rosser., Immunity 
2015 [85]
The literature aiming to define the role of B cells in colorectal cancer is still 
limited. A recent work from our group analysing the occurrence of B cells 
infiltrating human pancreatic adenocarcinoma has shown a peculiar duality of B 
cell spatial distribution in the microenvironment [74]. Specifically, the prognostic 
function associated to B cells infiltrating pancreatic cancer markedly changes 
according to the distribution of B cells in aggregates rather than randomly 
scattered in the microenvironment, thus suggesting that their spatial distribution 
in the tissue highly impacts on their function. There are few recent studies 
showing a characterization of the B cell infiltrate in colorectal cancer [71, 86], but a 
solid common idea on B cell role in this tumour is still lacking.
Biom arkers and Im m unoscore
In the first chapter, I have discussed the canonical classification of CRC and 
how the prediction of the clinical outcome is achieved. Usually, after surgical 
resection of the primary tumour, histo-pathological evaluation is performed.
The current staging system, based only on tumour invasion parameters, 
provides limited prognostic information and does not predict response to therapy. 
In some patients, advanced-stage cancer can be stable for years, and although rare, 
partial or full regression of metastatic tumours can occur spontaneously [50]. In 
contrast, relapse, rapid tumour progression and patient death is associated with 
25% of TNM I/II stage CRC patients, despite complete surgical resection and no 
evidence of residual tumour burden or distant metastasis [50]. The TNM staging 
focuses primarily on tumour cells and views tumour progression as a cell- 
autonomous process without considering the host immune response [87, 88].
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As I mentioned above, the tumour microenvironment influences cancer 
progression in different ways, depending on the tumour type and individual 
characteristics, thus being an important factor that cannot be ignored. 
Furthermore,: the importance of the host immune system in controlling tumour 
progression has profusely emerged. Nonetheless, the current system does not 
include it as an element to evaluate during tumour classification.
Histo-pathologic analysis of tumours have shown that the immune infiltrate is not 
randomly distributed: TILs are found within dense infiltrates in the centre of the 
tumour (CT), at the invasive margin (IM) of tumour nests and, as it has been 
recently demonstrated, in adjacent TLT. Therefore, inflammatory and lymphocytic 
cells, together with other elements of the tumour microenvironment, contribute in 
establishing the biology of the tumour. The analysis of the location, density and 
functional orientation of different immune cell populations, named "the immune 
contexture" [52] [Figure 3) in large cohorts of human tumours has allowed the 
identification of the components that are beneficial for patients and those that are 
deleterious [87, 89]. Since tumour features and immune reactions are connected, 
the emerging idea is to assess these factors and to investigate the effects of 
tumour-host interactions on clinical outcome and prognosis. In human CRC, the 
presence of TILs is associated to a favourable prognosis [61]. Pages et al [69] 
demonstrated that the presence of a high density of tumour infiltrating effector 
memory T cells correlates with the absence of early signs of metastasis. Moreover, 
time to recurrence and OS strongly correlate with the in situ adaptive immune 
reaction [61, 69,90, 91].
Evaluation of the histo-pathological immune reaction may provide novel 
information on prognosis and identify patient cohorts more likely to benefit from 
immunotherapy [92,93].
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Figure 3. The "immune contexture": schematic view of immune cell populations 
and immune structures [TLT], which should be included in the analysis of tumour 
features and could represent biomarkers of patient outcome. Adapted from 
Fridman, Nat Rev Imm 2012 [52]
Given the weakness of the TNM system and the important value of the 
immune cells, new systemic and local immunological biomarkers can be a 
significant innovative strategy in the prediction of outcome and response to 
therapy. Data demonstrating the impact of immune-classification in several human 
cancers are constantly growing; immune classification has a prognostic value that 
may strengthen the value of the TNM classification providing more information 
and facilitating clinical decision. The clinical translation of the studies 
demonstrating the prognostic value of the immune contexture in primary tumours 
is the establishment of an Immunoscore, a grading of tumours based on immune- 
histologic features.
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Galon et al. have proposed it as a useful tool based on the combined 
evaluation of memory and cytotoxicity markers for the prediction of tumour 
recurrence and survival in early-stage (TNM I and II] patients with CRC [94]. 
Specifically, the Immunoscore is based on the evaluation of two lymphocyte 
populations (CD3/CD45RO, CD3/CD8 OR CD8/CD45R0], both in the CT and in the 
IM of tumours, as a clinically useful prognostic marker in colorectal cancer. The 
Immunoscore provides a score ranging from immunoscore zero (10), when low 
densities of both cell types are present in both regions, to Immunoscore four (14), 
when high densities are found in both regions. This test has a dual advantage: first, 
it appears to be the strongest prognostic factor for DFS, DSS and OS, including at 
early-stage CRC; second, it has a biological meaning (adaptive immune response to 
tumours) and provides a tool or a target for novel therapeutic approaches, 
including immunotherapy (as recently shown in clinical trials boosting T cell 
responses with anti-CTLA4, anti PD1, anti PDL-1 [34, 94]). The Immunoscore 
approach has been applied to 2 independent cohorts (n=602). Only 4.8% of 
patients with a high 14 relapsed after 5 years and 86.2% were alive. In comparison, 
72% of patients with a low score (10 or U) experienced tumour recurrence and 
only 27.5% were alive at five years. These 10 and II patients potentially could have 
benefited from adjuvant therapy, had the Immunoscore been incorporated into the 
tumour staging [94].
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Basic aspects o f colon  anatom y
A considerable part of my thesis has been focused on the identification and 
characterization of lymphoid tissue in the human and murine colon mucosa. This 
analysis would not have been possible without a detailed knowledge of the colon 
anatomy and of the mucosal immune system. For this reason, I am going to provide 
a summary of the information I learnt, as a background to the later experimental 
part.
The human colon is part of the large intestine, together with the cecum, 
appendix, rectum and anal canal. It shares its basic structure with the remaining 
gastrointestinal canal. It is composed of four principal layers from the lumen 
outward:
- the mucous layer (mucosa)
- the sub mucosa
- the muscle layer
- the serous layer
Each layer has a predominant tissue type and a specific digestive function.
The mucous layer is covered by a simple lining epithelium with some 
important functions: to provide a selectively permeable barrier between the 
contents of the tract and other tissues and to facilitate the transport and digestion 
of food. The cells in this layer produce mucus and numerous digestive enzymes. 
Below the epithelium, there's a lamina propria of loose connective tissue rich in 
blood and lymph vessels and smooth muscle cells, sometimes containing also 
glands, many lymphoid cells and lymphoid aggregates (part of mucosal associated 
lymphoid tissue, MALT) important in defence against bacteria. The third 
component of the mucosa is the muscolaris mucosae, a continuous thin layer of 
smooth muscle separating the mucosa from the sub mucosa. It promotes the 
movement of the mucous layer independently of other movements of the digestive 
tract, increasing its contact with the food.
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The sub mucosa is composed of loose connective tissue containing elastic 
fibres, many blood and lymph vessels and the sub mucosal nerve plexus [or 
Meissner's plexus). It may also contain glands and lymphoid tissue. Lymphoid 
aggregates are frequently found crossing the muscularis mucosae and invade the 
sub mucosa.
The external muscle layer contains smooth muscle cells, spirally oriented, 
divided into two sub-layers according to the main direction the muscle cells follow, 
the myenteric nerve plexus [Auerbach's plexus) and blood and lymph vessels. The 
serosal layer is represented by the protective visceral peritoneum. It is composed 
of loose connective tissue, rich in blood and lymph vessels and adipose tissue and 
presents a simple squamous covering epithelium [mesothelium).
M ucosal im m unology
The large number of commensal bacteria and potential pathogens, shielded 
by only a single layer of epithelial cells within the intestinal lumen, is a continuous 
extraordinary challenge for the intestinal immune system [95]. In the human gut, 
trilions of bacteria are present, including more than 400 species, that feed 
themselves with alimentary products that an individual ingests, thus grow and 
proliferate. However, this "infection" is restrained. Indeed, bacteria are useful for 
the human organism, which allows them to grow taking advantage of their 
metabolic products as nutrients, as promoters of the intestinal absorption and as 
protective agents against pathogens and cancer. According to the complexity of the 
human gut flora and to the extension of the gut mucosa, that opens a wide gate for 
facing different pathogen agents [96], the intestinal immune system is huge and 
complicated, concomitantly challenged to fight against pathogens and to restrain 
the intestinal flora in the gut lumen.
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An equilibrium between the gut flora and the intestinal immune system is 
needed to ensure the digestive and absorptive processes [97,98]. Luminal bacteria 
neither cross the epithelial barrier nor seriously impair this equilibrium; at the 
same time, the intestinal immune system does not damage the "good" bacterial 
population. However, changes in dietary habits, ingestion of toxic compounds or 
infection with pathogens can perturbate this harmony, leading to alterations of the 
composition of the gut flora, damage to the epithelium, infection of the intestinal 
tissues and/or induction of inflammation.
The intestinal immune system is equipped with several "soldiers”, 
specialised in the maintenance of the equilibrium, including both single cell types 
and organised lymphoid aggregates, also known as gut-associated lymphoid tissue 
(GALT]. Among the main cellular populations, there are members of the innate and 
the adaptive immune system, such as intra-epithelial lymphocytes (IELs), dendritic 
cells [DCs], macrophages, mast cells, plasma cells and lamina propria leukocytes 
(LPLs). Besides immune cells, there are specialised epithelial and mesenchimal 
cells. All these elements constantly interact with each other to target bacteria in 
the gut lumen, in the epithelium or in the lamina propria. In particular, dendritic 
cells (DCs) sample antigens or live bacteria form these compartments and migrate 
to the T-cell zones of inductive sites, such as mesenteric lymph nodes and the 
Peyer's Patches (PP). There, DCs can induce adaptive immune responses that lead 
to the generation of effector T cells and of plasma cells that produce IgA, the main 
immunoglobulin that is manufactured by the immune system and secreted in large 
amounts into the gut lumen [9 5].
GALT is defined as an anatomically discernible lymphoid structure and can 
be viewed as an array of small lymphoid organs lining the intestinal tract. It is 
composed of highly specialised lymphoid organs, Peyer's Patches (PPs), and small 
lymphoid aggregations, Criptopatches (CPs) and isolated lymphoid follicles (ILFs). 
These organs constitute an adaptive response unit that monitors immunologically 
relevant events and maintains either tolerance or activates adaptive immune 
reactions [99].
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CPs have been hypothesized to play the role of primary lymphoid organs, 
supporting the extrathymic development of T lymphocytes, as well as to be 
precursor of mature ILFs, while PPs and MLNs are well defined secondary 
lymphoid organs involved in the induction of the mucosal immune response. In 
contrast, ILFs are tertiary lymphoid structures whose function is still under debate 
[100].
CPs and PPs develop during the embryonic life, starting from the 
recruitment of lymphoid tissue inducer (LTi) cells to specific sites of the 
developing intestine. This, in turn, stimulates the recruitment of dendritic cells, T 
cells and B cells, to organize the immune response to the microbiota. IELs colonise 
the epithelium before birth. Post-natally, after the colonisation of the neonatal 
intestine by the microflora, PPs complete their functional maturation and CPs 
develop into mature ILFs [101-103].
ILFs are present both in human [104] and mice [103]. Several clusters (100- 
200] can be found throughout the length of the anti-mesenteric wall of the mouse 
small intestine, as well as in the colon. ILFs are morphologically and functionally 
similar to the follicular unit that composes a PP and represent an alternative and 
inducible site for the induction of intestinal IgA antibody responses [103,105]. As 
mentioned above, ILFs development is triggered by environmental stimuli after 
birth, in particular by commensal bacteria or inflammatory stimuli. Their 
precursors, CPs, are phenotypically different and are mainly constituted by lineage 
negative cells (lin-), namely cells that do not express CD3, CD19, CDllb, CDllc but 
express SCF-R, cKIT and IL-7R. Several studies have demonstrated plasticity of 
these aggregates. In germ-free mice, the majority of lymphoid aggregates are very 
small, devoid of B cells, thus defined as CPs; after the colonisation by the micro­
flora from SPF (Specific Pathogen Free) mice, the composition of lymphoid 
aggregates changes, with the maturation from CPs to ILFs. Nonetheless, the 
number of these structures does not change and it is fixed during the first week of 
life [105].
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The observation that mice lacking PPs could still produce and secret IgA in 
response to luminal antigens led many to believe IgA CSR (Class Switching 
Recombination] could occur outside of organized lymphoid tissues [106, 107]. 
However following the identification of ILFs, these observations could be 
reinterpreted to support a role for ILFs in IgA production [108].
In inflammatory conditions, the number, diameter and density of ILFs 
increase, showing their plasticity and adaptability to the continuously changing 
intestinal environment. They participate not only to the immune surveillance, but 
also to the normal mucosal regeneration of the colon and they are likely to play a 
role in colorectal carcinogenesis [53,109], as it will be discussed later.
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Lym phoid organs
Over the past century, the importance of the existence of highly organised primary 
and secondary lymphoid tissues has been deeply highlighted. Since the immune 
system is extremely dynamic and its functioning is based on continuous 
interactions between diverse cell populations, the presence of specialised immune 
sites - lymphoid organs -allowing these peculiar interactions for the development 
of an effective immune response, emerges as very important.
The developmental process of lymphoid organs depends on the expression of 
specific molecules in a specific time frame during ontogenesis [110]. They can be 
classified in primary, secondary and tertiary lymphoid organs. The thymus and the 
bone marrow (liver in the fetal period] constitute the primary lymphoid organs, 
where the largest part of lymphocyte development occurs. In mammals, T 
lymphocytes both develop and mature in the thymus, while B cells develop in the 
fetal liver and in the adult bone marrow. During T and B cell differentiation, 
lymphocytes acquire their repertoire of antigen-specific receptors that represent 
the key point for adaptive immune response to pathogens in the periphery.
As to secondary and tertiary lymphoid organs, they share functional and 
architectural features, which need to be understood in order to perceive the 
relevance of investigating the occurrence of tertiary lymphoid tissue in tumours, 
which ultimately represented the aim of my thesis. For this reason, I will dedicate a 
section to the development and function of secondary and tertiary lymphoid 
organs and their similarities.
Secondary lymphoid organs (SLOs)
Secondary lymphoid organs include the spleen, lymph nodes (LNs] and the 
mucosa-associated lymphoid tissue (MALT), which includes PPs and ILFs. All these 
structures are essential for the induction of immune responses against pathogens,
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providing an ideal milieu for cellular and molecular interactions that lead to 
activation, differentiation and maintenance of lymphocytes, and facilitating the 
interaction between the immune system and microorganisms [111].
Three processes are strongly favoured by the presence of SLOs: first, they restrain 
pathogen spreading throughout the body, by organizing an adaptive immune 
response. Second, APCs sample antigens in the periphery and bring them into 
SLOs. Here, APCs meet their cognate pathogen-specific lymphocytes, giving rise to 
an efficient antimicrobial immune response. Third, SLOs are a reservoir of all the 
factors needed for survival and differentiation of lymphocytes [111].
Lymphoid organs develop with a complicated process during embryogenesis. A 
general model for lymphoid organogenesis is shared among SLOs, even if each 
organ needs different signals to completely form.
"it is the pervading law o f all things... that the life is recognizable in its expression, 
that form ever follows function". Based on this moral, Louis Sullivan designed the 
modern skyscraper, characterised by a strong steel frame. He wanted these 
buildings to provide an efficient microenvironment where people can easily travel 
through and connect with others, in every part of the structure. Likewise, SLOs are 
supported by a network of stromal cells that contribute to the division of the organ 
in specialised areas and to the connection of these. Thus, SLOs microanatomy 
accounts for its function, which is to mediate the immune system dynamics aiming 
at taking on the continuous infectious challenges from the environment [111].
Since the microanatomy of SLOs is similar under homeostatic conditions, I will 
briefly describe the lymph node (LN) to glance at the microarchitecture of these 
organs. A fibrous capsule and an underlying sub-capsular sinus surround the 
cellular contents of the LN. The cortex is made up of B cell areas organised in 
primary and, after antigen stimulation, secondary lymphoid follicles with GC 
[Germinal Centre). Inside the cortex there is the para-cortex, which is composed of 
T cells and DCs. The medulla consists of medullary cords, which are separated by 
medullary sinuses. The LN vasculature includes HEVs and lymphatic vessels. 
Lymphocytes circulate constantly through the LN by entering HEVs and exiting via
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efferent lymphatic vessels. DCs enter via afferent lymphatic vessels. Lymph with 
DCs and soluble antigen enters the LN at several points through afferent lymphatic 
vessels and deposits antigens in the subcapsular sinus.
Vascular and lymphatic endothelial cells are abundant non-hematopoietic cells in 
SLOs; they show a primary functional structure and they produce molecules, such 
as cytokines, through which they contribute in the dynamics within the LN. 
Specialised vascular endothelial cells of HEVs have a peculiar morphology and 
express molecules, such as PNAd (CD62L) and CCL21, that are extremely 
important for lymphocyte entry in the LN. Lymphatic endothelial cells express 
Lyvel, several adhesion molecules and CCL21, all involved in lymphocyte entry in 
lymphatics.
Once in the LN, cell location is "orchestrated" by lymphoid chemokines. CXCL13, 
expressed in the B cell follicles, guides B cells to them; CCL19 and CCL21, 
expressed in the T cell zone, positions T cells and DCs in the para-cortex. In 
addition, lymphoid chemokines expressed on HEVs facilitate the recruitment of 
lymphocytes to LN [112].
Therefore, secondary lymphoid organs represent a complex scenario in which 
immune responses take place; this scenario can be different depending on the 
pathological context. Therefore, SLO structure defines their function, but also the 
function influences the structure. The actors of the immune response can set up 
their stage: they adjust SLO microarchitecture depending on their needs during the 
life of the host [111].
Secondary lymphoid tissues develop during embryogenesis, thus during a specific 
and pre-determined moment, as well as in specific and predetermined places. 
Therefore, the time frame and the anatomical localization where they develop are 
always the same (Figure 4). Moreover, their formation does not depend on any 
antigenic nor inflammatory stimulus, but it represents a physiological process.
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Figure 4. Time-line of lymphoid organ development during ontogenesis. This 
picture shows that lymphoid organs do not all develop at the same time, but 
sequentially. Adapted from Mebius, 2003 [110]
Tertiary lym phoid tissue (TLT)
In contrast to SLOs, tertiary lymphoid tissues develop during the adulthood as a 
consequence of chronic inflammatory conditions, chronic infections or 
autoimmunity. As mentioned above, their formation is named lymphoid 
neogenesis. TLT can potentially develop in every part of the body: it does not 
appear in pre-determined nor predictable sites. Contrary to LN, TLT does not have 
an external capsule: this is an important feature, favouring antigen uptake in the 
peripheral tissues. Molecular and cellular mechanisms that control 
lymphorganogenesis during ontogeny have been deeply studied and identified, 
whereas, little is known about cells and pathways involved in lymphoid 
neogenesis. The frequent occurrence of TLT in inflamed tissues suggests a role for 
inflammatory mediators. Inflammation is a localised and thinly regulated response 
to an injury, tissue destruction and/or infections. Acute inflammation is an innate 
immune response, usually rapid and self-limiting. However, sometimes it does not 
resolve, turning into a persistent/non-resolving condition, which is chronic
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inflammation. This state promotes several pathological conditions, such as 
autoimmunity and cancer.
A focal characteristic of local inflammation is the interaction between immune 
cells and stromal cells that usually leads to resolution of the inflammatory 
response. During chronic inflammation, inflammatory mediators secreted by 
stromal cells lead to immune cell recruitment, activation, survival and, in this case, 
retention at pathological sites, with the persistence of the inflammatory lesion 
[113]. Buckley et al. assume that chronic inflammation involves immune cells 
being positioned in the wrong place at the wrong time.
During an inflammatory response, immune infiltration is usually seen as diffuse 
immune cells spread throughout the inflamed tissue. However, it is now well 
established that immune cells can also form organized aggregates in the targeted 
inflamed tissue, and these aggregates can take part to the developmental process 
of the pathologic state [112, 114-116]. The organized aggregates developing in 
peripheral non-lymphoid organs in pathologic conditions are called "ectopic 
lymphoid-like structures" (ELSs) or tertiary lymphoid tissue [TLT]. They share the 
structural organization with secondary lymphoid organs, showing 
compartmentalized B cell-rich and T cell-rich areas, specialized DC populations, 
activated stromal cells and HEVs. The phenomenon of TLT formation is termed 
lymphoid neogenesis [115,117] [Figure 5).
Pathologists have established that some criteria have to be fulfilled to define the 
presence of TLT: the presence of segregated areas of B and T cells; FRCs [Follicular 
Reticular Cells) within the T cell zone; PNAd+ or MECA79+ HEVs; evidence of B cell 
class switching or GC reaction in B cell area; expression of the enzyme AID; FDC 
[Follicular Dendritic Cells) within B cell zone. [117].
Studies on human pathologies and murine models have shown that there are at 
least three main events leading to lymphoid neogenesis during chronic 
inflammation: the expression of inflammatory cytokines, such as tumour-necrosis 
factor (TNF) and lymphotoxin [LT), the production of lymphoid chemokines by 
stromal cells and the presence of HEVs [112].
41
Avvh'aevv- vt- vwu \jS
i  \  ^
PV*&\V2
m ?
IL-i.
lu-Alu-'fe
IL~*
IL- 45 lls-U
Sa^^da^Y
& _ c « ( \  | o  l i t t l e
W rtk ©■Sl'WAd!
cevrtre
cti-i*
O G ru 'l  2. IcaK 4 .M^ bcAM 
fNAt? 
V C ^ H
Figure 5. Schematic model of cellular and molecular networks involved in 
lymphoid neogenesis. This picture represents the leukocyte populations and the 
key molecules involved in lymphoid organogenesis. The schematic lymphoid organ 
shows a T cell area (blue light cells) and a B cell follicle, including FDCs and 
plasmacells. FDCs have a pivotal role in the recruitment of B cells, producing 
CXCL13, and in their activation. FDC: follicular dendritic cells. Adapted from Aloisi, 
2006 [115]
Since TLT phenotypically appears similar to a secondary lymphoid organ, it has 
been wondered if the same processes occurring in TLOs, such as B and T cell 
priming or clonal expansion, can occur also in TLT. Does ectopic lymphoid tissue 
have a function? Can it contribute to the exacerbation of chronic inflammatory
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disease or in the protection of the host against pathogens? These questions have 
sharpened studies focused on lymphoid neogenesis in several diseases. [114,115].
Cellular and molecular determinants in lymphoid organogenesis.
As mentioned above, a general scheme that summarizes the developmental 
program of lymphoid organs has been elaborated. One of the crucial and earliest 
events in lymphoid organ formation is the interaction between two cell types: a 
haematopoietic lymphoid-tissue inducer cell (LTi) and a non-haematopoietic 
stromal lymphoid-tissue organizer cell (LTo), that respectively express the surface 
markers CD45+CD3-CD4+ IL-7R+c-kit+ and VCAM+ICAM+ [110]. The encounter 
takes place in the anlage (or primordium) that is an embryogenic active niche, 
where these Cells find a favourable microenvironment in which they accomplish 
their function.
LTi cells derive from common lymphoid progenitors in the fetal liver; the absence 
of the CD3 marker distinguishes them from lymphocytes. LTi cells express the 
chemokine receptors CCR7 and CXCR5 that promote their homing to those places 
where lymphoid organogenesis takes place.
LTo cells express lymphotoxin-(3 receptor (LT|3R) that binds its ligand 
lymphotoxin- ctifc (LTaifc) expressed on LTi cells. This binding leads to the 
release of lymphoid chemokines, including CCL19, CCL21, CXCL13, and the 
expression of adhesion molecules, fostering the recruitment of others LTi and 
lymphocytes. As B and T cells also express LTctifc, a positive feedback loop is 
created that leads to the local accumulation of more B cells and T cells [116,118]. 
From one hand, LTaifc expression controls the lymphoid chemokine production 
by stromal cells, from the other hand, lymphoid chemokine signalling on 
lymphocytes guarantees the expression of LTctifc on these cells. Blocking this loop 
in anywhere, leads to a defective lymphoid organ development and architecture 
[116] (Figure 6).
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It has been demonstrated that the injection of a soluble LTpR-immunoglobulin 
fusion protein during embryogenesis can block the development of lymphoid 
organs; and, depending on the timing of the injection, all or some SLOs do not 
develop, showing that lymphoid organs do not all develop at the same time, but 
sequentially [119].
LT is a multifunctional cytokine included in the TNF family. It has a similar 
structure to that of TNFa; indeed both molecules contribute to lymphoid 
organogenesis and the regulation of inflammatory and immune-regulatory 
responses. LT also controls the differentiation of stromal cells and HEVs and is 
important for the expression of several adhesion molecules on vascular 
endothelial cells and stromal cells. For example, LTa, LTa(3 and TNF signalling 
through their receptors control the expression of MAdCAM, PNAd, VCAM-1 and 
iCAM-1. Therefore, LT signalling has a key role in many aspects of SLOs 
development, lymphoid architecture and cell dynamics. The importance of its role 
has been confirmed studying the knock out murine model for LTa. This mouse 
lacks LN, PP and has an impaired architecture in the spleen [120].
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Figure 6. Schematic representation of the pivotal molecular and cellular 
events involved in lymphoid organogenesis. Lymphoid organogenesis is 
initiated by the interaction of lymphoid tissue inducer cells [LTi] with 
mesenchymal organiser cells. The first step includes the recruitment of LTi cells to 
mesenchymal cells through CXCR5 and the connection through VCAM1 and VLA4. 
As a consequence, LTal{32, expressed by LTi, interacts with LT(3R on LTo. This 
interaction induces local expression of lymphoid chemokines (CCL19, CCL21, 
CXCL13), which, in turn, attract T and B cells to the activation site. Since B and T 
cells also express LTal|32, they contribute to generate a positive feedback loop 
that leads to the local accumulation of more B and T cells and to the development 
of the organised microenvironment of SLOs. Adapted from Junt, 2008 [1 1 1 ]
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Although the majority of the developmental program of TLT is similar to that of 
SLOs, the mechanisms that trigger TLT formation are poorly defined, and for this 
reason studies focus on specific elements in each disease, from lymphoid 
chemokines, to cytokines as LT, to specific cell populations.
Presuming that SLOs and TLT organogenesis share the majority of molecular 
mechanisms, genetically modified mice for molecules involved in this process have 
been useful to study their role in the development of both SLOs and TLT. These 
models have allowed to understand that molecular mediators involved in TLT 
formation are mostly the same that guide lymphoid organogenesis.
An interesting aspect of the process of lymphoid neogenesis is the occurrence of 
lymphoangiogenesis [112]. Lymphatic vessels are associated to immune infiltrate, 
including B and T cells, raising the possibility that lymphatic endothelial cells 
actively recruit lymphocytes by expressing CCL21 [121]. Therefore, lymphatic 
neoangiogenesis contributes to the recruitment of infiltrate and even in the 
maintenance of a potentially detrimental alloreactive immune response in renal 
transplants, suggesting that lymphoangiogenesis and lymphoid neogenesis are 
connected. This suggests that lymphatic vessels could be a new therapeutic target, 
for instance, in autoimmune diseases, where TLT is likely to sustain the pathology 
[112]. Additionally, another field of therapeutic approach would be in cancer, 
where an increase of lymphatic drainage promotes metastasis [122].
TLT and pathology
Based on the pathological setting in which TLT occurs, the initial trigger can be of 
different nature, In general, it is recognized that tertiary lymphoid tissue develops 
during chronic inflammatory processes associated to autoimmune diseases [123, 
124], chronic infections [125] and cancer [53, 126, 127](Figure 7). Once 
established TLT presence and its morphological features, the next question would
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be whether it has a pathophysiological role in diseases. The function that TLT 
acquires depends on the organ in which it occurs and on the pathological context. 
The local microenvironment controls the development and function of TLT [127]. 
From one hand, it has been shown to support disease progression, acting as an 
alternative site for autoreactive lymphocyte recruitment and activation [128]; 
from the other hand, it can "protect” the organism by creating an immune response 
that restrains the pathological process [129]. Overall, detailed studies have shown 
that TLT shares with SLOs not only the microarchitecture but also functional 
properties, directing several B cell and T cell responses, including the induction of 
effector functions, clonal expansion, antibody generation, somatic hypermutation, 
affinity maturation, immunoglobulin class-switching [114, 115]. I will analyse 
different pathological settings in which TLT has been observed and which function 
it acquires in each disease.
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Figure 7. TLT in human diseases: the schematic representation shows groups of 
diseases in which the occurrence of TLT has been documented.
TLT in Autoimmune diseases
The presence of lymphocyte aggregates with the appearance of functionally 
ectopic immune sites has long been described in the inflamed target organs or 
tissues of patients who are affected by usually organ-specific autoimmune 
diseases, including the synovial tissue in rheumatoid arthritis [124], the meninges 
in multiple sclerosis [130], the salivary glands in Sjogren's syndrome [131], the 
thymus in Myasthenia gravis [132] and the thyroid gland in Hashimoto's 
thyroiditis [133]. In these clinical disorders, TLT develops in response to disease- 
specific auto-antigens, which also guarantee the maintenance of this lymphoid 
structure within the inflamed tissue [114]. Therefore, irt the majority of 
autoimmune diseases, TLT presence correlates with the in situ production of 
auto antibodies and an exacerbation of disease severity. It has been demonstrated 
that the regulatory mechanisms that govern tolerance within secondary lymphoid 
tissues are not maintained in TLT associated to autoimmunity. For instance, in 
SLOs, autoreactive B cells that recognize self-antigens may be excluded from 
entering germinal centres ant they downregulate CXCR5, thus not responding to 
CXCL13 [134]. Instead, TLT allows autoreactive B cells to entry in the target organ 
[135]. Here, B cells can differentiate into high-affinity autoreactive plasmacells that 
release autoantibodies directly in the organ affected by the disease, for examples 
anti-citrullinated protein antibodies (ACPAs] in rheumatoid arthritis [136], and 
antibodies against the ribonucleoprotein Ro and L in Sjogren's syndrome [137], 
against thyroglobulin and thyroperoxidase in Hashimoto's: thyroiditis [133]. 
However, despite all the evidence demonstrating that TLT is an immunologic 
active site present in patients with autoimmune diseases, it is still hard to define if 
TLT development leads to the disease or if the autoimmune disease leads to TLT 
[116].
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TLT in Chronic infection
Several viral or bacterial infections are associated to chronic inflammation that 
provides a strategy to avoid the spread of the infection to the whole organism. 
Lymphoid neogenesis in chronic infections is likely to be evolved as a new 
mechanism whereby containing the infective reaction where it arises. Therefore, 
infection-associated mucosal TLT can mount protective immune responses in situ 
[114, 115]. TLT occurrence has been documented in chronic hepatitis C virus 
(HCV) infection [138, 139], in H. Pylori-induced gastritis [125], in Lyme disease 
[140].
The infection of mice with H.pylori (HP) triggers the formation of lymphoid 
aggregates with GC in the gastric mucosa [129], while influenza virus and 
M.Tuberculosis induce lymphoid neogenesis in the lungs of rodents [141]. These 
data suggest that TLT, at sites of infection, drives a protective immune response in 
addition to, and often independently from, SLOs. However, a failure to eradicate a 
pathogen has considerable clinical implications and can lead to the development of 
autoimmunity (ex, chronic HCV infection) or lymphoma (ex HP associated chronic 
gastritis) [114].
TLT in Cancer
As I have discussed above, it is now well known that immune cells infiltrate human 
solid tumours, although the prognostic value of immune cells in cancer patients is 
variable according to the tumour type and stage of disease [52]. Overall, targeting 
immune infiltrating cells by immunotherapeutic approaches is one of the main 
goal of cancer research today [142].
In cancer, the presence of TLT has been documented in many tumours [143,144], 
including lung [127] [145], melanoma [146], ovarian [147], colon [53, 92, 148], 
breast [149, 150] and germ cell cancer [151]. However, not every patient with a 
specific type of cancer develops TLT and when it is present, its contribution to 
disease varies considerably. TLT develops more frequently in some tumour types
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than in others, suggesting that certain tumours provide a microenvironment that 
appears as a permissive milieu for lymphoid neogenesis. Moreover, TLT can show 
different levels of organization in different tumour types, changing from patient to 
patient. Such differences may reflect different stages in the program of lymphoid 
neogenesis, as previously suggested in non-transformed inflammatory settings. 
Finally, the density of TLT is heterogeneous even among tumours of a given type, 
once again reflecting the diversity of individual tumour microenvironments, being 
more or less permissive to lymphoid neogenesis [152].
The emerging evidence that the adaptive immune responses can be triggered 
independent of secondary lymphoid organs has been encouraging scientists in 
extend their knowledge of TLT. Depending on the tumour type and stage, TLT 
could have different roles. From one hand, the presence of TLT in tumours may 
represent an ectopic immune site where tumour antigens can be presented and the 
anti-tumour immune response can take place. From the other hand, the pro­
tumour role of chronic inflammation suggests that TLT may also represent a 
source of growth factors and pro-angiogenetic factors that sustains tumour 
progression. Moreover, lymphatic vessels associated to TLT may provide an 
additional way for cancer cell to spread to other parts of the organism.
One of the first reports of the occurrence of TLT in human cancer came from a 
study on breast cancer. Coronella et at. focused her attention on infiltrating ductal 
carcinoma (IDC) of the breast and investigated whether tumour-infiltrating B cells 
(TIL-B] represent a tumour-specific immune response [126]. They highlighted the 
heterogeneity of the lymphocytic infiltration with particular attention to the B cell 
component, which is present only in the 24% of the adenocarcinomas, but when 
present, it represents up to 40% of the TIL population. Interestingly, B cells appear 
as dense aggregates [153] that are often localized in stromal areas immediately 
adjacent to tumour nests. Lymphoid aggregates resemble lymph node germinal 
centres. The majority of B cells are IgG+, in contrast to the IgA+ population 
normally present in healthy breast tissue. Moreover, the B cell zone is surrounded 
by T cells and within B cell follicle there are CD21+ FDCs. Each characteristic 
makes these lymphoid aggregates good candidate as alternative immune site
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where B cells can get activated. Indeed, Coronella et al. demonstrated that TIL-B 
undergo tumour antigen-driven expansion in intra-tumour aggregates.
In 2008 Dieu-Nosjean reported the presence of TLT in non-small-cell lung cancer 
(NSCLC) [127]. The highly compartmentalization of TLT within lung tissue 
suggested that it could mediate an on-going immune response. As a potential 
mechanism for TLT formation, Authors showed that the more tumour were 
infiltrated by mature DCs expressing DC-LAMP, the more T and B cells were 
organized and proliferated in TI-BALT (Tumour Induced-Bronchus-Associated 
Lymphoid Tissue), suggesting a pivotal role for DC cells in TLT development. 
Moreover, a DC-Lamp high tumours had a higher density of TILs and accordingly 
high density of DC-Lamp+ DCs was associated with a favourable clinical outcome 
for patients with early-stage NSCLC.
Therefore, TLT seems to represent an active immune site, able to recruit T 
lymphocytes at the tumour site and to activate immune cells in the tumour 
microenvironment. Moreover, its density, when accurately assessed, can represent 
a prognostic biomarker. Thus, TLT assessment and targeting emerge as promising 
approaches for the design of novel prognostic immune signatures and 
immunotherapeutic strategies.
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Patients. We considered tissue specimens from 351 stage II and III patients 
without any sign of metastatic disease at diagnosis, who consecutively underwent 
radical surgical resection for pT3 or pT4 colorectal cancer (CRC) Patients' 
demographics, clinical and histopathological data were available and obtained 
from the Institutional Intranet. The equipe of clinicians who provided us the 
specimens confirmed that the absence of metastases at diagnosis had been 
assessed in all patients by combining histopathological findings, surgical records 
and perioperative imaging, according to institutional protocols. Similarly, to study 
the prediction of disease recurrences according to the state of immune infiltration, 
patients with pTl or pT2 CRC, who have a very low risk of progression at 
diagnosis, and patients with perioperatively detected metastases were excluded. 
To exclude potential confounders in the study design, stage I patients were not 
enrolled in the cohort studied for their unlikely occurrence of disease recurrence, 
while stage IV CRC patients were not included because they are characterized by 
the presence of distant metastases, which is an outcome event of our analysis. 
Patients who underwent neoadjuvant radiotherapy for rectal cancer were 
excluded from the study, because of the possibility of interference with the 
assessment of the local immune response. Chemotherapy treatment was 
administered and allocated by a non-random assignment, according to adjuvant 
protocols in use at the time of surgery.
Study design. We retrospectively studied tissue specimens of CRC patients who 
consecutively underwent radical surgical resection for pT3 or pT4 colorectal 
cancer (CRC) at the Humanitas Clinical and Research Center, Rozzano, Milan, Italy, 
from January 1997 to November 2005 were. Investigators who were blinded to the 
results of the morphological analysis assembled a clinical retrospective database 
by collecting demographics, clinical and histopathological data from the 
institutional intranet. These variables, together with the median values of CD3- 
TLT, CD3-TIL, CD20-TLT and CD20-TIL IRA%, were tested as predictors of 
patient's outcome. The outcome of patients who undergo radical resection of 
colorectal cancer is a variable affected by an event defined as any local tumour
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recurrences or any metachronous distant-organ metastasis and named disease 
free survival (DFS). To detect or exclude any postsurgical tumour recurrences, 
patients underwent thoraco-abdominal computed-tomography (CT) abdominal 
ultrasonography, and chest radiography, that were done according to common 
protocols for surveillance. The observation period started immediately after the 
surgical procedure. Time to follow-up was stopped at the time of the death of 
patient for any case unrelated to colorectal cancer disease, and this case was not 
considered an event of outcome. The mean follow-up period of the cohort studied 
was 4.71 years (SD = 2.63 years) for DFS. The detection of tumour recurrence or 
death was computed from diagnosis until data were censored on May 30, 2010. To 
further assess any possible biases, interaction analyses in predicting patient's 
prognosis were performed for all the variables assessed in order to detect any 
effect modifier (P<0.10).
Immunohistochemistry. From each patient enrolled in the study, 2 pm thick 
tissue slides from formalin processed and paraffin embedded tumour sections 
were processed for immunohistochemistry. After deparaffinization and 
rehydration, sections were immersed in an antigen retrieval bath, incubated with 
3% H202 for 15 minutes. Slides were autostained (IntelliPATH FLX, Biocare 
Medical) with primary antibodies raised against CD3 (clone F7.2.38, Dako), CD20 
(clone L26, Dako), DC-Lamp (clone 1010E1.01, Dako), PNAd (MECA-79, BD 
Pharmingen), Lyve-1 (abl4917, Abeam), CD21 (clone EP3093, Abeam), alfa-SMA 
(clone 1A4, R&D) CXCL13 and CCL21 (AF801 and AF457, R&D), IgA and IgG 
(polyclonal rabbit; Dako), Ki67 (MIB-1, Dako), BCL6 (PG-B6p, Dako), IL-10 
(polyclonal goat; R&D), PDL1 (rabbit polyclonal; abeam). A 30 minutes incubation 
with the DAKO Envision system (Dako) or Anti-Goat Polymer kit (Biocare) 
followed. Diaminobenzidine tetrahydrochloride (DAB) (Dako) was used as 
chromogen. Nuclei were lightly counterstained with a freshly made haematoxylin 
solution (Medite). Presence of fibrosis was assessed on 2 im-thick sections stained 
for 20 min with 0.1% Sirius red in saturated picric acid (Sigma-Aldrich). The 
sections were further washed in water, mounted and analysed under an optical
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microscopy. Slides were digitized using a computer-aided image analysis system 
[Olympus DotSlide, Olympus, Italy). TLT exhibited a distinct structural
organization in CRC, outlined by an area composed of CD3+ cells and a 
compartment of CD3 negative lymphoid cells [CD20+ B cells). To quantify immune 
cells, I randomly selected three non-contiguous microscopic areas located at the 
tumour invasive front occupied by either CD3-TLT or CD20-TLT. With the same 
approach three non-contiguous microscopic areas located at the tumour invasive 
margin including scattered CD20-TILs were selected at the interface between 
tumour stroma. Accordingly, cancer tissue in CD20-TILs microscopic areas had to 
represent approximately 50% of the entire microscopic field. Computer-assisted 
measurement of the selected areas was obtained as the percentage ratio between 
immunoreactivity and the total digitized tissue surface. For each histological 
section, the mean values obtained in three different regions were calculated and 
used for the subsequent statistical analysis. Median values of the overall 
distribution of the immune variables were chosen as representative cut-off to 
perform statistical analyses.
Statistical analysis. The association between the extent of the immune variables, 
patient's baseline characteristics and tumour features was estimated by Pearsons' 
simple linear regression analysis. A Cox proportional hazards model was 
developed to assess the role of the density of immune variables and other 
demographic, clinical and histopathological features, in predicting the occurrence 
of disease specific survival [DFS). To assess for confounders, COX multivariate 
analysis was performed by entering only variables and their significant 
interactions with a P value less than 0.20 at univariate analysis. Interactions 
between variables were calculated by analysing their multiplicative term in the 
Cox model. By a backward stepwise elimination approach, non-significant 
variables, and their non-significant interactions, were removed from the model. 
Interacting variables at multivariate analysis [P<0.10) were then tested for 
subgroups analysis accordingly. Differences in median values of immune variable 
density between subsets of CRC and DFS were tested by the Mann-Whitney U test
and by Cuzick's trend test. Kaplan-Meier curves of DFS were plotted, while log- 
rank test was used to compare the curves of each subgroup of CRC patients. For 
each test, only two-sided P values lower than 0.05 were considered statistically 
significant. All the analyses were done using Epi Info (Version 3.4.3], StatsDirect 
Statistical software (Version 2.5] and GraphPad Prism software (Version 4.1).
Quantification of HEV in human CRC. Consecutive tumour slides from 20 CRC 
patients were stained with antibodies raised against PNAd. For each tumour slide, 
the absolute numbers of PNAd positive vessels within each intratumour follicle 
and follicles associated to the normal mucosa were quantified.
Mice and murine models of CRC. 8-week-old C57BL/6J mice were purchased 
from Charles River (Calco, Italy); jiMT mice and eGFP/C57Bl/6 mice from Jackson 
Lab. Procedures involving animals and their care were conformed to Institutional 
Guidelines in compliance with National and International laws and policies. Mice 
were housed in a specific pathogen-free animal facility of the IRCCS Humanitas 
Clinical and research Center in individually ventilated cages. In the AOM/DSS 
model, mice developed adenomas as a result of the combined treatment with the 
carcinogen azoxymethane (AOM, 10 mg/kg; Sigma- Aldrich) and sequential 
administration of the mucosal irritant dextran sulphate (DSS) [3 rounds of 2 % DSS 
(MW = 36.000-50.000; MP Biomedicals)] in the drinking water. Adenomas develop 
in the distal colon overtime during the different treatments and are evaluated after 
10 weeks. In the genetic APCMin/AOM model, the formation of adenomas is 
induced by the weekly administration of the carcinogen AOM (10 mg/kg) in 
APCMin mice, once a week for 4 weeks, followed by sacrifice at 9 weeks. In both 
models, mice develop adenomas in the distal colon overtime during the different 
treatments and are evaluated after 10 weeks. In the implanted model, CMT93 
murine CRC cell line is injected subcutaneously. After three weeks, mice develop 
tumours.
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Immunofluorescence. Frozen sections of murine colons or colon whole mounts 
were stained with specific antibodies: B220 (clone RA3-6B2, e-bioscience) CD3 
(clone 145-2C11, e-bioscience), CDllc (clone N418, e-bioscience), CD21 (ep3093, 
Abeam), FDC (FDC-M1, BD Pharmingen), CXCL13 (polyclonal goat IgG; R&D), 
Lyvel (rabbit polyclonal, Abeam), PNAd (MECA-79, BD Pharmingen), MadCAM 
(MECA-367, BD Pharmingen), CD31 (clone 2H8, Millipore), CCL21 (clone 59106, 
R&D systems), CD8 (clone 4SM15; eBIOSCIENCE)
The three-dimensional visualization of B cell follicles was obtained on colon whole 
mounts; briefly, colons were removed from mice and immersed in 1% 
paraformaldehyde fixative solution overnight. Tissues were then washed and 
stained immunohistochemically by incubating whole mounts with primary 
antibodies diluted in PBS containing 0.3% Triton X-100, 2% bovine serum 
albumin, 5% normal goat serum, 0.01% glycine and 0.1% sodium azide overnight, 
followed by overnight incubation with secondary antibodies. The three- 
dimensional visualization of TLT in mMT mice was obtained on colon whole 
mounts by 3D visualization of cellular aggregates evidenced by Syto 13 Green 
Fluorescent Nucleic Acid Staining (Invitrogen).
Morphometric Analysis. Morphometric analysis of colon whole mounts was 
performed by 3D visualization of B220+ follicles. Isosurfaces were obtained by 
importing confocal RGB image stacks to Imaris software. For each colon analysed, 
one stack of each follicle identified was acquired and analysed. CD3+ cell 
enumeration was performed by computer-assisted image analysis on 20 pm thick 
sections of whole colons.
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Cell purification and transfer. Single-cell suspension of splenocytes from 
eGFP/C57BL/6 mice (Jackson Lab) was prepared, after red blood cell lysis. Cells 
were then washed, resuspended in PBS at a concentration of 10*106 and injected 
into the retro-orbital sinus of recipient animals. Mice were sacrificed after 24 
hours; colons were opened and frozen flat. GFP+ cells within TLT were 
enumerated on 20 pm thick frozen sections by confocal microscopy.
Enzyme Linked Immunosorbent Assay (ELISA) for murine immunoglobulins.
ELISA was used for the detection of immunoglobulins (Ig) in murine stool 
supernatants. Stool were collected, weighed and suspended in PBS and 0,05% 
sodium azide. Samples were submitted to sonication; then supernatants were 
recovered. Ig were measured with specific antibodies against various isotypes 
(anti-IgA, anti-IgM, anti-IgGl, anti-IgG2b, anti-IgG3) provided by SouthernBiotech. 
The protocol was performed as follows:
1. Coating with coating antibody (goat anti-mouse Ig) in carbonate buffer at 
4°C overnight;
2. Discard the coating antibody solution and wash the plate with PBS-Tween;
3. Block the plate with blocking solution (PBS/BSA 1%) for 1 hour at room 
temperature;
4. Discard the blocking solution and wash the plate;
5. Add mouse stool supernatant in duplicates to the plate and make serial 
dilutions (1:3) of standard murine Ig (starting at 625 ng/ml). Incubate for 2 
hours at room temperature;
6. Discard supernatants and wash the plate;
7. Add HRP conjugated goat anti-mouse isotype specific antibodies to the 
plate and incubate for 1 hour in PBS at room temperature;
8. Discard and wash;
9. Add Peroxidase substrate solution to the plate. Develop the plate at room 
temperature in dark;
10. Block the reaction with NaOH 3N and read the plate using an ELISA reader 
with a wavelength of 405nm;
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Lamina propria leukocyte (LPL) purification. The entire colon was removed, 
chopped with scissors into 1 cm small pieces and washed with HBSS/serum 5%. 
After washes, colon pieces were transferred into a solution containing 2mM EDTA 
and incubated for 20 minutes on a rocker (twice}. Then, samples were vortex 15 s 
at maximum setting and tubes were shacked. In order to allow pieces to settle, 
samples were centrifuged and supernatant were discarded. Then, tissue was 
transferred to an eppendorf tube and minced very well. Tissue was transferred 
again to a 14ml tube with Collagenase from clostridium hystoliticum (Sigma 
Aldrich} solution 0.5mg/ml and put on rocker for 30 min at 37°C. After 30 min, 
tissue was passed through 21G needle until parts are all gone and then poured 
through a 70 um cell strainer into a 50 ml tube. Once added RPMI, cells were 
centrifuged and supernatant was discarded. Pellet was resuspended with 5 ml of 
Percoll 44% and transferred into 15ml canonical tube. 7ml of Percoll 66% was 
added on the bottom of the tube, that was centrifuged for 20 min at 2000 rpm 
(brake low}. Once recovered cells, they were washed with RPMI and centrifuged 
for 6-7 min at 1500 rpm (at least twice}. Cells were ready for FACS staining or 
mRNA analysis.
FACS analysis. Flow cytometry was performed using FACS Canto II flow cytometer 
and the final analysis with Flowjo software (TreeStar}. LPLs were washed with 
FACS Buffer (PBS/BSA} and resuspended in a blocking solution containing mouse 
Fc Block (anti-mouse CD16/CD32 monoclonal antibody -  BD bioscience}. After 
blocking, cells were washed again and stained with several antibodies: anti-mouse 
CD45/PerCP (clone 30 F ll; eBIOSCIENCE}, anti-mouse CD19/APC (clone MB19-1; 
eBIOSCIENCE}, anti-mouse B220/PEcy7 (clone RA3-6B2; eBIOSCIENCE}, anti­
mouse CD3/FITC (clone 145-2C11; eBIOSCIENCE}, anti-mouse CD8/PacificBlue 
(clone 53-6.7; eBIOSCIENCE}, anti-mouse NK1.1/APC (clone PK136; 
eBIOSCIENCE}, anti-mouse F4/80/PE (clone A3-1; AbD SEROTEC), anti-mouse 
Ly6G/FITC (clone RB6-8C5; BD Pharmingen}.
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mRNA expression analysis. Total RNA was extracted from LPLs using QIAGEN 
RNeasy Mini Kit.
The reverse transcriptase PCR (RT-PCR) was performed using a High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems] according to the 
manufacture's instructions. Random primers were used. Applied Biosystems 
7900HT Fast Real-Time System was used to detect the expression of several genes. 
Fast SYBR® Green Master Mix and specific primers (designed by our laboratory) 
were used to prepare samples.
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Background and goal
This chapter will focus on the characterization of the CD3 compartment in the 
colonic mucosa of colorectal cancer patients and murine models, both in terms of 
tissue localization and cellular and molecular composition. As already discussed in 
the introduction, lymphoid tissue is present in normal colonic mucosa as part of 
the MALT and mediates important functions, including pathogen recognition, 
activation of an appropriate protective immune response, which principally 
involves secretory antibodies, particularly IgA. The aim of the analyses I am going 
to present was firstly to investigate the occurrence of TLT in the colon mucosa 
during carcinogenesis and which are the mechanisms driving TLT development. 
The ultimate goal was to test whether TLT has a clinical relevance in human CRC.
Tertiary lymphoid tissue in human colorectal cancer
Localization o f  TLT in human CRC
While the presence of lymphoid tissue, also known as isolated lymphoid follicles 
(ILFs}, in the normal colon mucosa has been well documented [103, 105], the 
occurrence and behaviour of inducible [or tertiary] lymphoid tissue [TLT] during 
carcinogenesis, has not been deeply investigated.
Since CD3+ T cells represent an important component of TLT, to investigate the 
occurrence of TLT in human CRC specimens, I first evaluated, by 
immunohistochemistry, CD3+ T cell infiltration. In human CRC specimens, CD3+ T 
cells are not only interspersed in the tumour tissue and scattered throughout the 
stroma as TILs [CD3-TILs] [Figure ID], but they also group into lymphoid 
aggregates [CD3-TLT], at the bottom of the crypts in normal mucosa [Figure 1A], 
and next to tumour nests [Figure IB] and in stromal region, at the invasive front 
of the tumour [Figure 1C]. These aggregates present a high degree of 
compartmentalization, with B and T cell areas, thus resembling TLT [53].
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Figure 1. Tertiary lymphoid tissue in human colorectal cancer specimens.
Immunohistochemical staining with an anti-CD3 antibody allows identification and 
distribution of CD3+ T cells in human CRC. CD3+ T cells localize in lymphoid tissue 
associated to normal mucosa, at the bottom of the crypts (A) and within TLT 
localized both adjacent to tumour nests (B) and in stromal regions (C); CD3+ T 
lymphocytes (TILs) are also scattered throughout the tissue as shown in [D]. Scale 
bars: 200 pm. Haematoxylin counterstaining.
Characterization o f  TLT in human CRC
Lymphoid tissue associated to normal mucosa has the typical organization of a 
lymphoid follicle within a secondary lymphoid organ (SLOs). To test whether the 
architecture of tumour-associated TLT is comparable to that of SLOs, I performed 
several stainings with specific antibodies that could highlight the presence of 
important cellular mediators usually found in lymphoid organs. Staining with anti- 
CD3 (FigureZA) and anti-CD20 (Figure 2B) antibodies revealed that tumour-
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associated TLT has compartmentalized T (CD3+) and B (CD20+) cell areas; 
follicular dendritic cells (CD21+) gather together within a B cell zone (Figure 2C). 
Mature dendritic cells are present within TLT, as evidenced by DC-LAMP 
immunoreactivity (Figure 2D), and may contribute to T cell activation [53].
An important feature of lymphoid organs is the presence of a vascular network, 
including lymphatic vessels and high endothelial venules (HEV), specialized 
haematic vessels that allow recruitment of naive lymphocytes [154]. 
Immunohistochemistry with an antibody against PNAd (Figure 2E-F) and Lyvel 
(Figure 2G), markers for HEVs and lymphatics respectively, was performed to 
investigate whether TLT is equipped with a vascular network, allowing trafficking 
of immune cells and the communication with the surrounding tissues.
Figure 2. Characterization of TLT in the colonic mucosa of colorectal cancer 
patients. Immunohistochemistry with antibodies against CD20, CD3, CD21, DC- 
Lamp revealed that TLT in human CRC specimens is composed of segregated areas 
of CD3+ T lymphocytes (A) and CD20+ B cells (B) as shown in consecutive 
sections; within the B cell zone, a core of FDC CD21+ (C) is present. DC-Lamp + 
mature DCs are interspersed within TLT (D). Vessels within lymphoid tissue 
include PNAd+ HEV (brown in E-F) as well as Lyve-1+ lymphatic vessels (pink in 
G), suggesting traffic of naive lymphocytes. Sections in E and F are consecutive 
sections, showing HEV and lymphatic vessels in the same follicle. Dot lines indicate 
follicle contour. Scale bars: 200 pm (A, D), 50 pm (C-E-F-G).
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Potential mechanisms driving TLT development during colorectal 
carcinogenesis.
Once established that TLT is a histologically distinct immune component in the 
microenvironment of human CRC and presents important features of lymphoid 
sites, including cell subsets and a specialized vascular network, I started to wonder 
which is the mechanism driving the formation of TLT during colorectal 
carcinogenesis.
The accurate compartmentalization of TLT suggests the involvement of specific 
molecular mediators released in the tumour microenvironment. In chronic 
inflammatory conditions, activated stromal cells are known to produce several 
inflammatory mediators, including chemokines, responsible for the infiltration of 
immune cells. Given the association between colorectal cancer and chronic 
inflammation and since TLT is preferentially localized in stromal regions, to test 
the hypothesis that stromal factors might be responsible for driving neogenesis of 
TLT, I analysed by immunohistochemistry the tissue surrounding TLT. I confirmed 
the presence of activated alpha-SMA+ fibroblasts (Figure 3A) surrounding and 
within TLT, and by Sirius Red, the presence of collagen fibres (Figure 3B) in the 
surrounding tissue. Moreover, I evaluated the presence of lymphoid chemokines 
CCL21 and CXCL13, which are both expressed within lymphoid tissue (Figure 3C- 
D), indicating active recruitment of cells and plasticity of TLT.
6 6
2 3 & M
aSM A Sirius CCL21 CXCL13
Red
Figure 3. Tumour associated inflamed strom a associates to formation of 
highly organized intra-tum our lymphoid tissue. Lymphoid tissue in human 
colorectal cancer specimens is usually located in stromal areas. Many alpha-SMA (a 
marker of local fibrosis and inflammation] positive cells are present in stromal 
areas surrounding TLT [A]; staining with Sirius Red indicates the presence of 
collagen fibres (B). The lymphorganogenic chemokines CCL21 (C) and CXCL13 [D] 
are present inside TLT. Dotted-circles indicate intra tumour lymphoid tissue. Scale 
bars: 200 pm.
Analysis o f  High Endothelial Venules in tum our-associated TLT
As I mentioned before, the process of lymphoid neogenesis includes new vessel 
formation, to allow proper circulation of immune cells. Antigen presenting cells 
(APCs) reach lymphoid organs through lymphatic afferent vessels, while naive 
lymphocytes through high endothelial venules (HEVs], specialized blood vessels, 
which direct the traffic of naive T cells [115].
I have shown that tumour-associated lymphoid tissue includes both lymphatics 
and HEV [Figure 2 in this chapter]. Therefore, to understand whether TLT 
occurrence was associated to a perturbation of the vascular compartment, I 
decided to compare the vascular network of lymphoid tissue associated to normal
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mucosa and intra-tumour TLT. HEVs were present mostly in the context of TLT 
and very rarely found in the surrounding tumour tissue. 1 found an increased 
number of HEVs in TLT within the tumour compartment (p <0.05) (Figure 4).
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Figure 4. Specialized haematic vessels increase in tum our-associated TLT. 
Figure 4 A shows a lymph node-like follicle associated to normal crypts devoid of 
HEV, while tumour-associated TLT has a high number of PNAd+ HEVs (brown in 
B). PNAd+ HEVs significantly increase in tumour associated TLT compared to 
those in lymphoid tissue associated to normal mucosa (C). HEVs were quantified 
by computer assisted image quantitative analysis on slides from 20 paraffin 
embedded cancer tissue specimens stained with an anti-PNAd antibody. Bars in C 
represent the number of HEV in each lymph node like follicle. Scale bars: 200 pm.
* p < 0.05 by Student's T test.
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The expansion of HEVs in tumour-associated TLT suggests it may have an active 
role in lymphocyte recruitment at the tumour site. Furthermore, HEV development 
is one of the earliest events during lymphoid neogenesis, when lymphocytes have 
to be recruited to the neo-formed lymphoid organ. In the tumour context, this 
would mean that intra-tumour TLT develops de novo, during carcinogenesis, and it 
may have active functions in the tumour microenvironment.
Evaluation o f the relationship between TLT and tumour-infiltrating 
CD3+ T cells in colorectal cancer.
While CD3+ T cell density is recognized as a prognostic marker for CRC patients 
[60, 61], the mechanism for CD3+ T cell recruitment and activation at the tumour 
site has not been identified.
The expansion of HEVs raises the hypothesis that there could be an association 
between tumour-infiltrating CD3+ T cells and TLT. It may be that TLT contributes 
to T cell recruitment at the tumour site in colorectal cancer and the recruitment 
may be mediated by TLT-HEVs.
To address this point, I systematically evaluated by immunohistochemistry with an 
anti-CD3 antibody the density of CD3-TLT at the invasive front, in 351 tissue 
specimens (Figure 5A) and quantified the area of CD3-TLT by computer-assisted 
image analysis. The cohort of patients includes stage II (SII) and stage III (SIII) CRC 
patients, whose clinico-pathological features are summarized in Table 1. Whole- 
tissue analysis of the CD3+ infiltrate showed a higher density of CD3-TILs in 
tumours containing high density of CD3-TLT (Figure 5C), compared to tumours 
containing low density of lymphoid tissue (Figure 5B). In fact, I found a positive 
correlation between CD3-TIL density and CD3-TLT density (R = 0.29; p <0.001) 
(Figure 5D). Together with the increased amount of HEVs within CD3-TLT, the 
correlation of CD3-TLT density and CD3-TILs suggests that TLT may be involved in 
T cell recruitment; this result has important clinical implications, considering the 
positive prognostic value that CD3-TILs have in human CRC.
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Figure 5. Increased T cell infiltration associated to intra tumour lymphoid 
tissue. Figure 5 A shows a representative image obtained by virtual scan of a 
colorectal tumour specimen. Staining with anti-CD3 antibody allows identification 
of lymphoid tissue. Asterisks indicate TLT in the tumour stroma, at the invasive 
front. (B-C) representative images of two colorectal tumour specimens with low 
(B) and high (C) degree of T cell infdtration and TLT. Asterisks indicate TLT. (D] 
Correlation between CD3+ TILs density and TLT density in 351 CRC patients. 
Patients with a high density of TLT also have a high density of CD3+ T 
lymphocytes, p value by simple linear regression analysis. Scale bars: 1 mm
Tertiary lymphoid tissue in murine models of colorectal cancer
Cellular and molecular components of the microenvironment of human CRC allow 
neogenesis of tertiary lymphoid structures. Tumour-associated TLT develops 
preferentially in stromal regions, where activated fibroblast producing 
chemokines and cytokines are present. In our cohort of stage II and III CRC 
patients, TLT density positively correlated with the density of TILs, suggesting that 
it may be involved in lymphocyte recruitment.
In order to increase our knowledge on the mechanisms driving TLT development 
and the role of TLT in T cell infdtration in CRC, I have taken advantage of different 
preclinical models of CRC. These models have allowed me to elucidate the role of 
chronic inflammation in triggering TLT formation and to verify the hypothesis that 
TLT mediates lymphocyte recruitment at tumour site.
71
Visualization o f TLT in the murine colonic mucosa
As in human CRC specimens, I started with localization and characterization of TLT 
in the murine colon mucosa. Also in the mouse colon, aggregates of lymphocytes 
are present in homeostatic conditions, as part of the GALT, and play an essential 
role in the immune response to perturbations of the mucosal microenvironment 
[155].
Lymphoid follicles in the murine colon mucosa mostly localize in the lamina 
propria and sub mucosal region of the intestine and can be visualized by 
Haematoxylin-Eosin [H&E] staining of horizontal sections of the intestine, as dense 
aggregates of lymphocytes [Figure 6A). I then performed several specific stainings 
with antibodies directed to B220, CD3, CDllc and CD21, in order to highlight the 
heterogeneity and compartmentalization of lymphoid tissue. As expected, the 
majority of the cells composing TLT are B220+ B lymphocytes [Pink, figure 6B], 
while CD3+ T lymphocytes represent a minor component [light blue, figure 6B). 
CDllc+ dendritic cells constitute an important element of TLT [green, figure 6C). 
Another important population is represented by CD21+ FDC [green, figure 
6B/6D), which play a key role in B cell recruitment, activation proliferation. In 
fact, they represent the major source of the lymphorganogenic chemokine CXCL13 
[blue, figure 6D].
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Figure 6. Characterization of TLT in the m urine colonic mucosa. A
representative image obtained by virtual scansion of a section of murine colon 
mucosa stained with Haematoxylin-Eosin. Asterisks indicate TLT (A). Staining with 
B220 antibody allows identification of TLT, since B cells are the major population. 
B (pink, B) and T cells (light blue, B) hold complementary positions within TLT. A 
core of FDCs (green, B} is present in the B cell area. CDllc+ DC (green, C,)are 
spread among B cells (pink, C]. FDCs (green, D) are an important source of CXCL13 
(Blue, D}. Scale Bars: 200 pm (A), 50 pm (B-D]
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Analysis o f  TLT in preclinical models o f CRC
My previous analysis of TLT in human CRC suggests that a reactive stroma 
associated with carcinogenesis may provide proper signals inducing lymphoid 
neogenesis. To confirm the contribution of chronic inflammation to TLT formation, 
I evaluated its effect in two CRC mouse models:
- a mouse model of colitis-associated cancer (AOM/DSS)
- a genetic mouse model of CRC not driven by an inflammatory process 
(ApcMin/AOM).
In the first model, adenomas develop after AOM/DSS treatment due to the synergic 
action of the carcinogen (AOM] and the mucosal irritant (DSS) that causes chronic 
colitis (Figure 7A). In the second model, AOM treatment favours the formation of 
polyps in the distal colon of ApcMin mice that usually have polyps in the small 
intestine (Figure 7B).
In order to quantify TLT in the mucosa of tumour-bearing mice, I performed whole 
mount staining with an anti-B220 antibody, identifying B cells, which are the most 
represented population within TLT in the gut. Then I calculated the area of TLT by 
morphometric analysis. My results show that in the colonic mucosa of AOM/DSS 
treated mice there is a strong increase in the total area covered by B220+ TLT 
compared to control mice (Figure 7C); on the contrary, in ApcMin/AOM mice 
there is no a significant modification of lymphoid tissue area (Figure 7D), 
confirming the important role of inflammation in TLT development.
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Figure 7. Chronic inflammation drives expansion of TLT in a preclinical 
model of CRC. Schematic protocol of AOM/DSS administration in the colitis- 
associated colorectal cancer model (A) and of AOM administration to ApcMin mice, 
in the genetic model of colorectal cancer not driven by an inflammatory reaction 
(B). At the end of the protocol, mice develop adenomas in the distal colon. The area 
of TLT was evaluated both in colon whole mounts of mice developing colonic 
adenomas and control mice. The area of TLT significantly increased after 
inflammation-induced polyp formation (C), while there was no significant 
modification of lymphoid tissue area in mice developing non-inflammation-driven 
adenomas (D). *** p < 0.001; Two-tailed p value by Student's t test.
•21
. 0 -
. 8 -
. 6 -
,4*t
,4 -r
. 2 -
* 1
^5  ^ »•&
— i---------------1--------------- r ----------1 r
#2 #3 4 1  #2 43
D.S
0.5
E
E 0.3
o
u .
0.0
41 42 43 4 1  #2 43
TLT m ediates T cell infiltration in a murine m odel o f  inflammation- 
driven CRC
I have previously discussed how TLT density positively correlates with CD3+ T cell 
density, supporting the idea that TLT is involved in T cell recruitment at the 
tumour site.
Since TLT increases in tumour-bearing mice compared to controls, I asked 
whether this expansion correlates with an increased amount of T cells reaching 
TLT. In order to answer this question, I quantified T cells by staining colon sections 
with an anti-CD3 antibody. Quantification revealed that control mice had very few
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or none T cells within TLT (Figure 8 A-B), differently from tumour-bearing mice, 
which show a well defined T cell zone (Figure 8C].
CTRL TUMOR
Figure 8. Expansion of TLT associates to increased num ber of CD3+ T cells.
Staining with an anti-CD3 antibody allows the identification of T lymphocytes. In 
the colonic mucosa of control mice, TLT is almost completely devoid of T cells (A). 
On the contrary, a considerable number of T cells are present in tumour-associated 
TLT in AOM/DSS treated mice (B). There is a significant increase of CD3+ cell 
number in tumour-bearing mice compared to control mice (C). CTRL, n=6; 
AOM/DSS, n=6; scale bars: 200 pm; ** p < 0.01 by Student's t test.
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Analysis o f  the vessel netw ork associated to TLT in a murine m odel o f  
inflammation-driven CRC
As I highlighted above, the process of lymphoid neogenesis includes new vessel 
formation. In human CRC specimens, I have demonstrated the presence of both 
lymphatic vessels and HEVs, the latest increasing in tumour-associated TLT 
compared to TLT in the normal mucosa. In light of these previous results, I have 
analysed the vessel network surrounding and within TLT in AOM/DSS treated 
mice and controls. Staining with anti-CD31 antibody (Figure 9 A], anti-Lyvel 
(Figure 9A) and anti-PNAd (Figure 9B) revealed the presence of haematic and 
lymphatic vessels and specialized blood vessels, HEVs.
Figure 9. Characterization of the vessel netw ork associated to TLT in the 
AOM/DSS model. Tumour-associated TLT contains CD31+ haematic vessels (pink, 
A] as well as Lyvel+ lymphatic vessels (green, A). PNAd+ HEV are present within 
TLT (orange, B). Scale bars: 200 pm (A), 50 pm (B)
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Quantification o f  CD31+ lym phatic vessels in AOM/DSS murine m odel
To get insights into the mechanisms of vascular increase associated to TLT 
formation in colorectal cancer, I have quantified the vascular network surrounding 
TLT in the AOM/DSS model. In control mice, mucosal crypts are surrounded by a 
polygonal network of vessels and lymphoid tissue is drained by a regular vascular 
supply (Figure 10A). In contrast, TLT in the colon mucosa of tumour-bearing mice 
is surrounded by a dense network of haematic and lymphatic vessels (Figure 
10B). Staining of colon whole mounts followed by morphometric tridimensional 
analysis of the lymphatic network allowed a precise evaluation and revealed a 
significant increase of lymphatic vessels draining TLT in mice with tumours 
compared to control mice (Figure IOC).
Ctrl AOM/DSS
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Figure 10. Quantification of the lymphatic netw ork draining TLT in AOM/DSS 
m urine model. The lymphatic network draining TLT in the colon mucosa of 
tumour-bearing mice (B) is expanded compared to control mice (A). Visualization 
of CD31+ vessels (grey in A and B) surrounding B220+ TLT (red). Lymphatic 
vessels were discriminated from CD31+ haematic vessels based on the 
morphology and the intensity of the staining. n=6 mice, CTRL; n=6 mice AOM/DSS; 
bars represent SEM. Scale bars: 200 urn . *** p < 0.001 by Student's t test.
Among haematic vessels, some expressed the markers MadCAM and PNAd, 
associated to HEVs (Figure 9B-C). In many sections, CD3+ T cells were adherent to 
HEVs, suggesting an active role of these vessels in lymphocyte recruitment (Figure 
11A). Quantification of PNAd expressing haematic vessels revealed that tumour- 
associated TLT contained a higher number of PNAd+ HEVs, compared to TLT in the 
normal mucosa (Figure 11B), this accounting for an increase in the vascular area 
of these specialized vessels (Figure 11C).
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Figure 11. Quantification of HEVs in tum our-associated TLT in the AOM/DSS 
model. High magnification of PNAd+ HEV (red, A) CD3+ T lymphocytes circulating 
into HEVs, being in close proximity to their luminal surface, are present (asterisks, 
green, A). Quantification of HEV by computer assisted image analysis. Both number 
(B) and total area (C) of HEV increase in TLT of tumour-bearing mice compared to 
control mice. Scale bar: 30 urn; ** p < 0.01 by Student's t test.
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Role o f  TLT in lym phocyte recruitm ent a t the tum our site
Our data, both in CRC patients and in the AOM/DSS preclinical murine model of 
CRC, indicate that a high density of TLT correlates with a higher density of CD3+ T 
cells, suggesting that TLT is involved in lymphocyte recruitment. In order to 
demonstrate the contribution of TLT to lymphocyte recruitment at the tumour site, 
I injected intra venous GFP+ splenocytes both in controls and in AOM/DSS treated 
mice. After 24 hours, very few or none GFP+ cells localized within TLT associated 
to normal mucosa (Figure 12A); conversely, a considerable amount of GFP+ cells 
localized in tumour-associated TLT (Figure 12B).
Figure 12. Transfer of GFP+ splenocytes into control and tumour-bearing 
mice. GFP+ splenocytes from wild-type mice were intravenously injected into 
AOM/DSS treated and control mice; mice were sacrificed after 24 hours from the 
injection and colons analysed by confocal microscopy. While TLT is almost devoid 
of GFP+ cells in colonic mucosa of control mice (A), a considerable number of GFP+ 
cells localized in TLT in the colonic mucosa of AOM/DSS treated mice (B). 
Quantification of GFP+ cells within TLT is shown, each dot refers to a single 
lymphoid follicle (C). Scale bars: 200 pm; *** p<0.001 by Student’s t  test
Clinical relevance of TLT in human CRC
The evaluation of CD3+ tumour-infiltrating lymphocytes (CD3-TILs) in the colonic 
mucosa of CRC patients has been object of intense studies, which have led to the 
remarkable conclusion that CD3-TILs contribute to an anti-tumour immune 
response and are associated to a favourable prognosis in CRC patients.
Once established that there is a close relationship between CD3-TLT and CD3-TILs, 
the next step aimed to understand the clinical significance of CD3-TLT. Table 1 
summarises clinico-pathologic features of patients included in our cohort.
CD3-TLT was present in 276 (78,6%) of 351 CRC specimens, with a density median 
value of 2,68%. In order to investigate the clinical relevance, I correlated CD3-TLT 
density with clinical parameters and follow-up (disease-free survival, DFS). 
Univariate analysis showed that high (>median) CD3-TLT and CD3-TIL density 
significantly correlated with better outcome [HR, 0.62; 95% confidence interval 
(Cl), 0.40-0.97]. However, Cox multivariate analysis considering all the variables 
revealed an interaction of CD3-TLT and CD3-TILs with nodal status in predicting 
patients relapse, which suggests that the ability of CD3-TLT and CD3-TILs to 
predict patients relapse may change according to nodal status (Table 2).
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n___________ [%1
Patient Agea
<69 yrs 187 53%
>69 yrs 164 47%
Patient Gender
Male 196 56%
Female 155 44%
Tumor Site
Colon 263 75%
Rectum 88 25%
Tumor Invasionc
pT3 311 89%
pT4 40 11%
Nodal Statusd
NO 185 53%
Nl 106 30%
N2 60 17%
Tumor Gradee
G1/G2 288 82%
G3 63 18%
Tumor Cell Typef
Adenocarcinoma 319 91%
Variants 32 9%
Vascular Invasion
No 273 78%
Yes 78 22%
MS-Status s
MSS 291 83%
MSI 60 17%
5-FU Treatment
Stage II No 108 58%
Yes 77 42%
Stage III No 48 29%
Yes 118 71%
Table 1. Demographics and clinico-pathologic features of 351 CRC.
a Age entered as a continuous variable.c: pT3: invading through the muscularis propria into 
subserosa or into non-peritonealized pericolic or perirectal tissues. pT4: directly invading adjacent 
organs or perforating visceral peritoneum.d: NO: no lymph node involvement. Nl: 1-3 nodes 
involved. N2: more than or equal to 4 nodes involved.e: Gl: well differentiated. G2: moderately 
differentiated. G3: poorly differentiated.f: Variants mucinous or medullary, s: MSI: microsatellite- 
unstable. MSS: microsatellite-stable.
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Relapse Univariate Analysis Multivariate Analysis
TLT density
<Median
>Median
TIL density
<Median 
>Median 
Age (years, Std D e v )a 
Gender 
Male 
Female 
Tum or MS Status 9 
MSS 
MSI 
Tum or Site 
Colon 
Rectum 
Local invasion c 
pT3 
pT4
Tum or Nodal Status d
NO
N1
N2
No Yes HR (95% Cl) p
(n = 2 6 7 ) (n = 84 )_________________________
HR (95% Cl) p
125 51 1.00 (reference) 1.00 (reference)
142 33 0 .62(0.40-0.97) 0.03 0 .72(0.46-1.14) a
136 50
131 34
(66.94, 11.45)
1.00 (reference) 
0.74(0.48-1.15) 0.18
1.00(0.98-1.02) 0 .6 4 1
1.00 (reference) 
0.83(0.53-1.30) p
145 51
122 33
1.00 (reference)
0.81 (0.52-1.26) 0.35
215 76 1.00 (reference)
52 8 0 .56(0.27-1.16) 0.12
214 49 1.00 (reference)
53 35 2 .24(1.45-3.46) <0.001
1.00 (reference) 
1.87(1.20-2 .92) 0.006
242 69 1.00 (reference)
25 15 1.95(1 .11-3 .42) 0.01
159 26 1.00 (reference). 1.00 (reference)
78 28 1.99(1.16-3.39) 0.01 1.98 (1.16-3.39) a, P
30 30 4.44 (2.62-7.53) <0.001 3.75 (2.19-6.41)
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Tum or Grade
G1/G2 222
G3 45
Tum or Cell T y p e f
Adenocarcinoma 245
Variants 22
Tum or Vascular Invasion
No 214
Yes 53
5-FU Treatm ent
Stage II 
Stage III
66 1.00 (reference).
18 1.33(0.79-2.24) 0.28
74 1.00 (reference)
10 1 .42(0.73-2.75) 0.29
59 1.00 (reference)
25 1 .64(1.03-2.63) 0.03
No 108 17 1.00 (reference)
Yes 77 14 1.36 (0.63-2.94) 0.42
No 36 26 1.00 (reference)
Yes 98 48 0.65 (0.38-1.15) 0.14
Table 2. Univariate and Multivariate Cox hazard model for predictive factors of 
d isease  relapse in 351 pT3/pT4 CRC.
a: Age entered as a continuous variable, a, and 0: the density of TLTs (>median; a) and the density of TILs 
(^median; p) are interacting with the occurrence of nodal metastasis in predicting patient’s relapse (P=0.07 
and P=0.03 respectively). Cox proportional hazard model: Hazard ratio (HR) less than 1.00 represents a 
decreased likelihood of patients’ relapse, whereas a HR greater than 1.00 represents an increased 
likelihood. Multivariate analysis was performed by entering only variables with a P value less than 0.20 at 
Univariate analysis. By a backward stepwise elimination approach, non-significant variables, and their non­
significant interactions, were removed from the model.
c: pT3: invading through the muscularis propria into subserosa or into non-peritonealized pericolic or 
perirectal tissues. pT4: directly invading adjacent organs or perforating visceral peritoneum.d: NO: no lymph 
node involvement. N1:1-3 nodes involved. N2: more than or equal to 4 nodes involved. e: G1: well 
differentiated. G2: moderately differentiated. G3: poorly differentiated.f: Variants mucinous or medullary.9: 
MSI: microsatellite-unstable. MSS: microsatellite-stable.
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To dissect better this aspect, I performed subgroup analysis, evaluating the 
prognostic function of CD3-TLT and CD3-TILs in subgroups of patients, according 
to their nodal status. Subgroup analysis revealed that in patients with node­
negative CRC (Stage II; n=185], a high density of CD3-TLT (>median, 2.68%] and of 
CD3-TILs (>median, 2.06%} was associated with better prognosis compared to 
patients with a low density of CD3-TLT and CD3-TILs (log-rank test, p = 0.02 in 
both cases] (Figure 13A-B, left]. Conversely, CD3-TLT and CD3-TIL densities were 
irrelevant to predict the prognosis of patients with node-positive CRC (Stage III; 
n=166] (log-rank test, p =0.46 and p = 0.64, respectively] (Figure 13 A-B, right], 
thus behaving as prognostic biomarkers only in early stage CRC.
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Figure 13. Clinical relevance of tumour-associated TLT and TILs in 351 CRC 
patients. (A-B) Kaplan-Meier curves showing disease-free survival (DFS), 
according to TLT and TIL density. A high density of TLT (>median, 2.68%) and of 
TILs (> median, 2.06%) is associated with better outcome in patients with node­
negative CRC (p =0.02, n=185) (A-B, left), but not in those with node-positive CRC 
(p =0.46 and p =0.64 respectively, n=166) (A-B, right). (C) Coordination of TLT 
and TIL immune infiltration. Distribution of TLT IRA% according to the CD3+ 
density (>median) in relapsing and not relapsing stage II CRC patients. TLT and 
TILs correlate only among patients that do not relapse.
We then hypothesized that CD3-TLT and CD3-TILs have a comparable prognostic 
impact and to better understand their relationship in the tumour 
microenvironment, we analysed their correlation according to disease 
progression. What we found was that CD3-TLT correlates with CD3-TIL density 
only in patients who did not experience relapse (p = 0.001), but not in those who 
relapsed (p =0.28) (Figure 13C), thus suggesting that the two biomarkers are 
coordinated in mediating the antitumor response only among patients with a good 
prognosis.
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Discussion
In this first part, I presented data on the characterization and the clinical relevance 
of tertiary lymphoid tissue in colorectal cancer.
From the first immunohistochemical analysis of human colorectal cancer 
specimens, I observed that CD3+ tumour-infiltrating lymphocytes are present both 
interspersed within the tumour tissue and in the stroma and they also aggregate in 
lymphoid structures, showing features of TLT. One of the main characteristics of 
TLT is the peculiar structural organization, with distinct cell compartments and 
specialized cell subsets, interacting each other to maintain a potentially functional 
environment.
Specifically, further immunohistochemical analysis with specific antibodies 
highlighted the compartmentalization of tumour-associated TLT, where CD3+ T 
cells and CD20+ B lymphocytes hold complementary positions, with several 
classes of dendritic cells among them. DC-Lamp+ mature dendritic cells are 
present scattered throughout lymphoid tissue and CD21+ follicular dendritic cells 
constitute a core within B cell zone.
In a physiologic context, lymphoid organs orchestrate lymphocyte trafficking, 
guiding them through a network of lymphatic and specialized haematic vessels. 
Interestingly, analysing the vascular network associated to TLT, I found both 
Lyve+ lymphatic vessels and PNAd+ specialized haematic vessels, HEVs. The 
presence of HEVs suggests a role for TLT in T cell recruitment at tumour site, while 
lymphatics suggest a possible active process of lymphocyte migration in and out 
the tumour site. Importantly, HEVs were present primarily in the context of TLT 
and very rarely in the surrounding tumour tissue. Analysing this specific vascular 
network within TLT, I found an increase in HEV number in intra-tumour TLT 
compared to ILF associated to the normal mucosa. This finding points out de novo 
formation of tumour-associated TLT, during carcinogenesis, and, since HEVs are 
used to direct the traffic of naive T cells, suggests the possible active role of TLT in 
lymphocytes recruitment at tumour site. Thus, the idea is that the more TLT with
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HEVs is present in the tumour context, the more tumour-infiltrating lymphocytes 
can reach the tumour. This process of lymphoangiogenesis is mediated by 
interactions between the vascular endothelium and immune cells, among which 
dendritic cells seem to have a pivotal role [156,157]. Concerning haematic vessels, 
in several solid tumours TLT-associated HEVs mediate T cell recruitment and 
correlate with a better clinical outcome.
In order to test the hypothesis and to find a relationship between TLT and TILs, I 
performed a whole tissue analysis of CD3+ infiltrate on CRC patient sections. This 
analysis showed a positive correlation between CD3+ T cell density and TLT 
density. Patients with a high density of CD3-TLT also had a high density of CD3- 
TILs infiltrating the tumour. The mechanism of the correlation between CD3-TLT 
and CD3-TILs can be explained by the increase in HEV network in tumour- 
associated TLT. Thus, the vessel expansion in tumour associated TLT suggests a 
possible key role of TLT in the recruitment of CD3+ T cells to the tumour site.
I then investigated the clinical significance of CD3-TLT in relationship with CD3- 
TILs in a large cohort of CRC patients. The most important finding was that a high 
density of CD3-TLT and CD3-TILs associate to a better prognosis only in patients 
with node-negative CRC, while in patients with node-positive CRC CD3-TLT and 
CD3-TIL density are irrelevant to predict the prognosis. These results highlight the 
similar prognostic behaviour of CD3-TLT and CD3-TILs, confirming their 
relationship in the tumour microenvironment. Importantly, CD3-TLT and CD3- 
TILs are independent prognostic markers for better prognosis in stage II CRC and 
their prognostic relevance is comparable.
The presence of specific subsets of cells within TLT has been investigated as key 
determinant of the anti-tumour function of TLT. For instance, it has been 
demonstrated that the positivity for the markers DC-Lamp or CD20 within TLT is 
predictive of prognosis in lung cancer and melanoma [54, 127, 152]. Significantly, 
in lung cancer the prognostic value of DC-Lamp+ cells within TLT was significantly
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independent of CD8+ T cells, and when matched as immune signature, their 
prognostic relevance was highly increased [158]. Consequently, TILs were likely 
dependent from DC-Lamp+ TLT to exert their anti-tumour activity and to facilitate 
the identification of lung cancer patients with better prognosis.
The accurate compartmentalization of TLT presumes the presence and 
involvement of specific molecular mediators released in the tumour 
microenvironment. The developmental process of TLT resembles the physiological 
process of SLO formation, but it occurs in the inflamed areas of several 
pathological conditions [115, 117,159]. In this context, the triggering event is the 
reactivation of stromal cells in local tissues by inflammatory mediators, such as 
lymphoid chemokines [160]. The presence of TLT that has been reported in 
several tumour types is in line with the relationship between chronic inflammation 
and tumour development, as the inflamed tumour microenvironment favours TLT 
development. In chronic inflammatory conditions, activated stromal cells are 
known to produce several inflammatory mediators, including chemokines, 
responsible for the infiltration of immune cells. The hypothesis that the chronic 
inflammatory response associated to tumorigenesis may be the trigger for TLT 
development has been confirmed by staining collagen fibres (Sirius Red) and 
activated fibroblasts (alpha-SMA), revealing the presence of a reactive stroma 
surrounding tumour-associated TLT, suggestive of an inflammatory 
microenvironment. Moreover, the expression of CXCL13 and CCL21 by a-SMA 
mesenchymal cells suggested an active recruitment of B and T cells and plasticity 
of TLT. Thus, the stromal reaction in colorectal cancer is likely to drive the 
formation of intra-tumour lymphoid tissue organized as TLT.
Besides the highly organized microarchitecture and the complexity of the cellular 
and molecular network, an important point that could help understanding the 
mechanism of TLT formation is the localization of TLT in the mucosa of colorectal 
cancer patients. Interestingly, TLT is located at the invasive front of the tumour, 
within the stroma. Its special location helps in summarizing three important 
points:
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- the presence of TLT within the stroma confirms the important 
contribution of stromal cells to the formation of intra-tumour lymphoid 
tissue;
- intra-tumour TLT has a distinct localization compared to lymphoid 
tissue associated to the normal mucosa (under the crypts). This allows 
to argue that tumour-associated TLT formation takes place during 
tumour development, thus representing a process of lymphoid 
neogenesis;
- TLT is located at the invasive front and this may account for its 
involvement in the anti-tumour immune response.
At this point, preclinical murine models have helped me to better clarify and 
confirm the role of chronic inflammation in TLT formation and the association 
between TLT and TILs.
As in humans, in murine colon mucosa ILFs are already present in homeostatic 
conditions, as part of the gut-associated lymphoid tissue and are located in the 
lamina propria of the colon. Immunofluorescence analysis pointed out the 
heterogeneity and compartmentalization of ILFs, with a prevalent B cell 
population, few T lymphocytes and CDllc+ dendritic cells. Importantly, a core of 
CD21+ FDCs is present within B cell zone; these DCs play a key role in B cell 
recruitment, with CXCL13 production, activation and proliferation. Since in 
biological science, in most cases structure is related to function and function 
strictly depends on structure, the highly organisation of murine ILFs, as in humans, 
suggests they should have important roles during individual life. First of all, I 
demonstrated that in a murine model of inflammation-driven CRC, TLT expands in 
tumour-bearing mice compared to controls, while in a murine model of CRC not 
directly related to inflammation I didn't find any difference between control and 
tumour-bearing mice. This confirms the important role that chronic inflammation 
has in TLT development.
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Then I analysed TLT behaviour in the inflammation-driven preclinical model. 
Going deeper into TLT function, I found that the number of CD3+ T cells within 
TLT is higher in tumour-bearing mice, differently from controls that have very few 
or none T cells, as I have previously demonstrated in CRC-patients. When TLT 
expands, there is an increased amount of T cells reaching TLT. Asking how these T 
cells reach lymphoid tissue, I have shown that tumour-associated TLT is well 
vascularized by CD31+ haematic vessels and Lyvel+ lymphatics. Among CD31+ 
haematics that increase during tumorigenesis in the surrounding tissue of TLT 
HEVs play the principal role in mediating T cell recruitment. Indeed, I observed a 
strong increase of these specialized haematic vessel, that correlates with the 
increased T cell infiltration in tumour-bearing mice. The final evidence that TLT is 
involved in lymphocyte recruitment at the tumour site came from an experiment 
of cell transfer. GFP+ splenocyte i.v. injection showed that a considerable amount 
of these cells reached tumour-associated TLT.
Therefore, TLT is associated with lymphocyte infiltration in CRC, being involved in 
TIL recruitment. CD3-TLT and CD3-TILs work together to set up an anti-tumour 
immune response in patients with low-risk early-stage colorectal cancer. Thus, 
CD3-TLT represents a novel prognostic biomarker for CRC.
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PART II
B CELL 
DISTRIBUTION
IN
COLORECTAL
CANCER
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Background and goal
This part of my thesis will focus on a key population among immune cells 
infiltrating colorectal tumours: B cells. In the introduction, I have discussed about 
the duality of B cell role in cancer and how the impact of B cells on the clinical 
outcome of cancer patients is debated. On one hand, B cells can produce antibodies 
or act as APGs, promoting the anti-tumour activity of tumour-infiltrating T cells 
[77, 78,161]; from the other, the production of antibodies and cytokines can foster 
tumour development in a paracrine fashion [81, 82, 84]. In addition, subsets of B 
cells with regulatory function have been recognized and involved in cancer 
progression [72, 73]. Collectively, despite still controversial, increasing evidence 
that B cells play a role in cancer progression has been provided [162], bringing up 
the hypothesis that also B-cell responses should be considered as targets of 
immunotherapeutic approaches. I have already shown the presence of B cells 
within TLT in human colorectal cancer patients and in preclinical models of CRC. 
The next step was to gain insights into the role of B cells in colorectal tumours and 
investigate whether they have a prognostic significance.
B cells in human colorectal cancer
B cells in human colorectal cancer
In the previous part of the results I focused my attention on tumour infiltrating 
CD3+ T cells, Showing their peculiar distribution within tumour tissue. In a similar 
manner, focusing on B cells, I stained tissue slides from human CRC specimens 
with an anti-CD20 antibody. As shown in Figure 14, CD20+ tumour-infiltrating B 
cells localized both in tertiary lymphoid tissue in the stromal compartment [CD20- 
TLT) [Figure 14A] and scattered around the tumour margin (CD20-TILs) [Figure 
14B].
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Figure 14. Distribution of B cells in the colonic mucosa of colorectal cancer 
patients. Representative images obtained by virtual scansion of a colorectal 
tumour specimen. Staining with anti-CD20 antibody shows that B cells distribute 
both within TLT (CD20-TLT, dotted circle] in the tumour stroma at the invasive 
front (A) and scattered around the tumour margin (CD20-TILs, dotted line) (B). 
Counterstaining with haematoxylin. Scale bars: 500 pm.
Antibody secreting cells (ASC), i.e. activated B cells, are abundantly present in the 
normal colon mucosa, most of them producing IgA. In order to investigate whether 
the physiological function of B cells changes in tumour conditions, I analysed their 
immunoglobulin profile. Staining with anti-IgA and anti-IgG antibodies revealed 
that the majority of B cells infiltrating the normal colon mucosa are IgA+ (Figure 
15 A), consistent with the repertoire of B cells in the secretory mucosal epithelium 
during homeostasis. On the contrary, very few or none tumour infiltrating B cells, 
including CD20-TLT and CD20-TILs were IgA+ (Figure 15B); they appeared 
predominantly as IgG+ cells (Figure 15C), suggesting a different antigenic 
response compared to normal colonic mucosa. In this regard, recent works have 
shown an important immunosuppressive function for IgA expressing B cells [73], 
while tumour-antigen specific immunoglobulins can be crucial triggers of 
anticancer cellular immune responses [161].
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Figure 15. Immunoglobulin expression on tumour-infiltrating B cells.
Immunohistochemistry with anti-IgA [A-B) and anti-IgG (C) antibodies on human 
colorectal cancer slides. In the normal colonic mucosa, as appears in A, most of B 
cells in the lamina propria are IgA+. In contrast, in tumour tissue, there are few 
IgA+ B cells (B) and there is a high prevalence of IgG+ tumour-infiltrating B cells, 
including B cells within TLT (C). Counterstaining with haematoxylin. Scale bars: 
500 pm.
The presence of a germinal centre within the B cell area of lymphoid tissues is 
mandatory for the development of both high-affinity class-switched antibodies and 
memory humoral immune response. With the aim to understand if CD20-TLT 
could be site for organizing a humoral immune response, I assessed by 
immunohistochemistry if B cells express two markers of activated germinal 
centres. Staining with anti-Ki-67 (Figure 16A), indicating cell proliferation, 
revealed a group of cells that strongly expressed this marker within TLT. 
Moreover, staining with anti-BCL-6 (Figure 16B), a transcriptional factor that 
regulates a program of genes required for GC function, showed some positive cells, 
thus confirming the presence of active germinal centres within TLT. Overall, the 
profde of the B cell compartment of TLT suggests that this immune site is fully 
equipped to sustain B cell activation in human CRC.
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Figure 16. Expression of germinal centre m arkers in tum our-associated 
CD20-TLT. Immunohistochemistry with anti- Ki-67 (A) and anti- Bcl6 (B] 
antibodies on human colorectal cancer consecutive slides. In figure A, a Ki-67 core 
of cells is present in TLT. In figure B, some positive BCL-6 cells are present in the 
same area where Ki-67+ cells localized. Scale bars: 100 pm (A), 200 pm (B}
Prognostic relevance ofB  cells in human colorectal cancer
Once established how B cells localize in the tumour context, I asked whether the 
two distinct components differently contribute to the immune microenvironment 
in human CRC. In order to answer this question, I systematically and quantitatively 
evaluated the percentage of immune reactive area (IRA%] of CD20+ cells at the 
tumour invasive margin, by considering CD20-TLT and CD20-TILs as distinct 
immune populations. This analysis has been done on 204 tissue specimens from 
stage III CRC patients (Table 3]; thus, compared to the previous analysis 
performed on T cells, we only considered Stage III patients. Whole tissue analysis 
highlights that CD20+ cells preferentially located within TLT compared to 
interspersed CD20-TILs (Figure 14A-B). Indeed, the density of B cells in TLT is 
significantly higher compared to the density of scattered CD20-TILs (Figure 17A), 
suggesting that B cells within TLT represent a predominant population compared 
to scattered CD20-TILs cells.
Next step was to investigate the clinical relevance of both CD20-TLT and CD20- 
TILs in a retrospective cohort study. To test the prognostic independency of 
immune biomarkers, we performed a Cox multivariate analysis, with respect to
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other demographics, clinical, histo-pathologic features in colorectal cancer (Table 
4). Multivariate analysis showed that CD20-TLT associated with better prognosis 
independently by any other variable included in the model (p=0.01), while CD20- 
TILs did not (Table 4). This result indicates that only TLT accounts for the 
prognostic relevance of B cells in human CRC, suggesting that the influence of B 
cells on tumour progression differs whether they are localized within lymphoid 
tissue or are interspersed at the tumour-host interface.
To gain further insights in the different prognostic behaviour of B cells and the 
relationship between CD20-TLT and CD20-TILs, we analysed the linear regression 
among the density of CD20-TLT and CD20-TILs according to CRC patient's disease 
progression. Multiple linear regression analysis revealed that the density of CD20- 
TLT independently correlated with the density of CD20-TILs (r=0.16; p=0.02, 
N=204), consistent with the ability of TLT to mediate recruitment of B 
lymphocytes. However, CD20-TILs correlated with CD20-TLT only among patients 
who experienced tumour recurrence, (r=0.40, p<0.001, N=71) (Figure 17B), while 
the correlation was lost among CRC patients with good prognosis (r=0.10, p=0.21, 
N=133) (Figure 17C). Thus, in sharp contrast to the relationship of CD3-TLT with 
CD3-TILs I have shown in the previous chapter, the correlation between CD20-TLT 
and interspersed CD20-TILs occurs only in patients who experienced recurrence of 
disease, suggesting that recruitment of CD20-TILs might reflect pro-tumour 
inflammatory pathways and that in the CRC microenvironment distinct 
populations of B cells critically regulate tumour progression.
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Table 3. Patient demographics and tumour features according to densities of 
CD20-TLT arid TILs and CD3-TILs in 204 stage III CRC.
Immune Reactive Area (IRA%) a b
CD20-TLT CD2 0-TIL s CD3-TIL s
n (%) Median P Median P Median P
All cases 204 (100) 2.01 0.17
Patient demographics
Age <50 yrs. 15 (7.0) 2.51 0.11 8.33
50-70 yrs. 102 (50.0) 2.23 0.39 0.21 0.90 1.99 <0.001
£7 0  yrs. 87 (42.6) 1.78 0.10 0.21 0.25 2.15 <0.001
Gender Female 128 (62.7) 1.89 0.21 2.39
Male 76 (37.2) 2.04 0.98 0.09 0.09 1.99 0.51
Tumour features
Nodal N l 132 (64.7) 2.20 0.19 2.33
Invasion N2 72 (35.3) 1.50 0.06 0.14 0.66 2.07 0.02
Angio pT3 141 (69.1) 2.20 0.21 2.00
Invasion pT4 63 (30.9) 1.40 0.20 0.10 0.04 2.37 0.58
Local pT3 173 (88.4) 2.01 0.17 2.24
Invasion pT4 31 (11.6) 1.86 0.99 0.16 0.75 2.01 0.79
Grade c
G1/G2
G3/G4
154
50
(84.8)
(25.5)
2.01
1.86 0.52
0.17
0.18 0.76
2.18
2.53 0.58
Tumor ADC 179 (87.7) 2.04 0.18 2.24
type Mucinous d 25 (12.2) 1.23 0.35 0.08 0.18 1.79 0.92
Dx 73 (35.8) 2.36 0.21 3.36
Site Sx 74 (36.3) 1.80 0.27 0.18 0.91 1.99 0.05
Rectum 57 (27.9) 1.74 0.15 0.08 0.71 1.74 0.08
Chemotherapy (CTX)
Adjuvant No 62 (30.4) 1.50 0.11 2.04
99
therapy Yes 142 (69.6) 2.17 0.26 0.18 0.14 2.23 0.20
Immune infiltrati on
CD20-TLT < M edian 103 (50.5) 0.10 1.64
(IRA%)a > M edian 101 (49.9) NA NA 0.28 0.02 f 3.06 O.OOlf
CD20-TILS < M edian 102 (50.0) 1.31 1.93
> Median 102 (50.0) 2.80 0.02 NA NA 2.87 0.10 f
(IRA%) a f
CD3-TILS < Median 103 (50 .5 ) 1.65 0.15
(IRA%) a > M edian 101 (49.9) 2.42 0.00 0.21 0.10 f NA NA
a Density is expressed as percent immunoreactive area at the tum our invasive margin. b linear 
regression analysis; CD20-TLT and TILs and CD3-TIL densities were entered as dependent 
continuous variables.c G1/G2, well-to moderately differentiated; G3/G4, poorly differentiated. d 
ADC: adenocarcinom a.e mucinous, signet-ring, or medullary histology.f multiple linear regression 
analysis, immune variables w ere entered together in the model. NA not applicable.
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Figure 17. Distribution of B cells in spatially distinct com partm ents and their 
correlation in human CRC. (A-C) Density of B cells in TLT (CD20-TLT) is 
significantly higher compared to density of scattered CD20-TILs, highlighting how 
B cells preferentially localize within tertiary lymphoid tissue in human CRC. ** p < 
0.01 value by Student's t test (A). Linear regression between the distributions of 
CD20-TLT and of CD20-TILs according to CRC patient's disease progression. CD20- 
TLT and CD20-TILs correlate only among patients who relapse [B] (p <0.001; 
r=0.4; n=71), while they do not correlate in patients who do not relapse (p <0.21; 
r=0.1; n=133) (C); p value by Pearson simple linear regression analysis.
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Table 4. Predictors of post-surgical disease specific recurrences in 204 
patients with nodal invasive pT3/pT4 colorectal cancer patients.
Univariate 
Analysisa
Multivariate 
Analysis a
Recurrence 
Rate (%)
H.R. (95%C.I.) P H.R. (95%C.I.) P
< 1.00 ref. 1.00 ref.
CD20-TLTb > 0.44 (0.27- 0.001 0.54 (0.33 0.01
Median 0.73) 0.89)
CD20-TILsb < 1.00 ref.
> 0.67 (0.42- 0.10
CD3-TILsb < 1.00 ref.
> 0.98 (0.62- 0.94
Age <50 1.00 ref.50-70 0.71 (0.27- 0.48
>70 1.27 (0.50- 0.62
Gender Female 1.00 ref.
Male 1.11 (0.69- 0.66
Nodal N1 1.00 ref. 1.00 ref.
invasion N2 2.74 (1.71- <0.001 2.35 (1.46- <0.00
4.38) 3.77) 1
Angio No 1.00 ref. 1.00 ref.
invasion Yes 2.42 (1.51- <0.001 1.96 (1.22- 0.005
3.86) 3.15)
Tumor cell ADC 1.00 ref.
tvne Variant 1.26 (0.64- 0.50
Local pT3 1.00 ref.
invasion pT4 1.32 (0.72- 0.36
Gradec G1/G2 1.00 ref.
G3 1.63 (0.98- 0.06
Tumor site Dx 1.00 ref.
Sx 0.70 (0.39- 0.24
Rectum 1.31 (0.75- 0.34
MS-Status MSS 1.00 ref.
MSI 0.78 (0.34- 0.57
Adjuvant No 1.00 ref
treatment Yes 0.61 (0.38- 0.05
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a COX regression analysis,b Densities as percent of immunoreactive area at the 
tumour invasive margin.
c G1/G2, well-to moderately differentiated; G3, poorly differentiated.
* By a backward stepwise elimination approach, non-significant variables (P<0.20) 
were removed from the multivariate model.
B cells in murine colorectal carcinogenesis
B cells in murine colorectal carcinogenesis: theAOM/DSS model
To expand our knowledge on the role of B cells in colorectal cancer and dissect the 
duality of the B-TLT and B-TIL immune components, I took advantage of two CRC 
preclinical models showing a different distribution of B cells in the 
microenvironment: the AOM/DSS model, characterized by well-defined TLT [53] 
and the implantable CMT93 model, which doesn't show organised structures, 
likely due to the rapid tumour growth [21 days) and absence of chronic 
inflammatory reaction. I also took advantage of mice lacking B cells [|iMT), to 
investigate the contribution of B cells in the tumour microenvironment.
As a first step, I evaluated by flow-cytometry the number of B220+ cells in the 
colon mucosa of AOM/DSS treated mice and controls. To this aim, I isolated 
leukocytes from the lamina propria (LPL) and stained them with different 
antibody cocktails [Figure 18-19). Flow cytometry quantitative detection of 
immune cells in the tumour colon mucosa of AOM/DSS treated mice revealed a 
massive infiltrate of CD19+/B220+B cells as compared to controls [Figure 18A-B). 
A further analysis of B cells by immunofluorescence with anti-B220 antibody 
revealed that B cell distribution in the murine colon mucosa is similar to that found 
in human CRC specimens, with B220+ B cells localized in two distinct 
compartments, either scattered in the stroma of tumour tissue as interspersed 
cells [B220-TILs; dot line) or as a component of tertiary lymphoid tissue [B220- 
TLT; dot circle) [Figure 18 D).
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Figure 18. B cell analysis in a preclinical model of colorectal cancer.
B cell number increases in AOM/DSS treated mice compared to controls, as 
summarised in dot plots (A), which represent respectively B cells from controls 
and tumour-bearing mice, and in the histogram (B). Histograms represent mean of 
three experiments (n = 6 mice, Ctrl; n = 12 mice AOM/DSS; bars represent SEM). * 
p <0.05 by Student’s t test. Frozen sections of murine colon from control mice (C) 
and AOM/DSS mice (D) stained with anti-B220 antibody (red}. B cells showed a 
dual localization: they are a major component of TLT (dotted circle, D] and they 
also localize interspersed in the tumour tissue (dotted line, D]. Scale bars: 100 
pm. * p < 0.05 by Student's t test.
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Once established that B cell number increases in AOM/DSS treated mice compared 
to controls, I wondered how B cells affect other leukocyte populations infiltrating 
CRC. To address this question, I analysed by flow cytometry the distribution of 
different leukocyte populations in wt mice and in mice lacking B cells (|iMT], both 
treated with AOM/DSS. A staining with several antibodies (anti-CD3, anti-CD8, 
anti-NKl.l, anti-F4/80, anti-Ly6G] revealed that there is a significant increase in 
leukocyte infiltration in pMT AOM/DSS treated mice compared to wt AOM/DSS 
treated mice (Figure 19].
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Figure 19. Analysis of the immune infiltrate in wt vs pMT AOM/DSS treated 
mice. The recruitment of immune cell populations increases in pMT AOM/DSS 
treated mice, as summarised in dot plots [A-B]. There is a significant increase of 
CD3+ T cells and CD8+ T cells (A-C) and of macrophages and neutrophils (B-C). * p 
< 0.05 by Student's t  test
In the previous chapter, I have shown that the treatment of wt mice with AOM/DSS 
induces the expansion of lymphoid tissue associated to the colon mucosa, with B 
cells representing the major population [53]. Due to the absence of B cells in pMT 
mice, in order to visualize lymphoid aggregates, I have stained pMT colon whole 
mounts with Syto green, a specific dye for nuclei. Surprisingly, while B220-TILs are 
absent in the colonic mucosa of pMT/AOM/DSS mice [Figure 20A), nuclear 
staining evidenced aggregates of cells resembling TLT [Figure 20A), thus 
suggesting that B cells are not dispensable for TLT formation. TLT in the colon 
mucosa of pMT/AOM/DSS mice included a dense core of CDllc dendritic cells 
[Figure 20B], scattered CD3+ T cells [Figure 20C], PNAd+ high endothelial 
venules (HEV) (Figure 20D), Lyvel+ lymphatic vessels and the lymphorganogenic 
chemokine (CCL21] (Figure 20E) suggesting that, although devoid of B cells, TLT 
is fully equipped to mediate T cell recruitment, which represents its important 
function.
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Figure 20. Characterization of TLT in pMT AOM/DSS treated mice. Colon 
whole mounts have been stained with syto green (Green in A], anti-B220 (red in 
A), anti-CD 11c (B), anti-CD3 (C). Frozen sections have been stained with anti- 
PNAd (D], anti-Lyvel (green in E] and anti-CCL21 (red in E) antibodies. TLT is 
present even if its major component (i.e. B cells] is absent (A]. The majority of cells 
are CDllc+ dendritic cells (B) PNAd+ HEVs (D] and Lyve+ lymphatics (green, E). 
The lymphorganogenic chemokine CCL21 is also present and associated to 
lymphatic endothelium (red, E). Scale bars: 100 pm (A-C], 50 pm (D-E).
Quantification of TLT confirms that, despite B cell deficiency, TLT expands during 
carcinogenesis, although to a lesser extent than in wt mice (Figure 21].
Figure 21. Quantification of TLT in pMT /AOM/DSS mice. Colon whole mounts 
have been stained with Syto 13 green, in order to visualize cell nuclei, thus 
allowing the identification of lymphoid tissue, which appears as a dense aggregate 
of nuclei. TLT density has been evaluated by morphometric analysis on colon 
whole mounts. There is a slight but not significant expansion of TLT in pMT 
/AOM/DSS mice compared to pMT controls,. ** p < 0.01 by Student’s t  test
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To investigate the contribution of B cells in the colorectal cancer 
microenvironment, I evaluated tumour growth in B cell-genetically deficient mice 
(^MT). Ablation of B cells significantly increased the number of adenomas in the 
colorectal mucosa (Figure 22). Considering the prevalent distribution of B cells 
within TLT in the colon mucosa of AOM/DSS mice (Figure 18D), this suggests that 
B cells within TLT might exert an important antitumour function. These data are in 
accordance with our human data and show that B cells within TLT seem to restrain 
tumour growth.
20-
1 20'oc
■8 15-Q
*Q -  10
WT mMT
Figure 22. Evaluation of tumour growth in the pMT/AOM/DSS model.
Quantification of adenomas in the AOM/DSS preclinical model. AOM/DSS treated 
pMT mice show a higher number of polyps compared to AOM/DSS treated wt mice. 
n= 6 wt, n= 6 uMT; * p < 0,05 by Student’s t test
The antitumour role of B cells within TLT could be related to a variety of B-cell 
functions, including the capability of TLT to sustain a germinal centre reaction. 
Since I have already shown that B cells in the human colorectal mucosa are 
predominantly IgG+, both dispersed and localized within tumour-associated TLT, I 
also analysed the Ig repertoire expressed by B cells in the CRC preclinical model. I 
quantified the concentration of immunoglobulins by an ELISA assay performed on 
supernatants recovered from mouse stool, representative of the production of Ig in 
the colonic mucosa. I have quantified IgA, IgM, IgGl, IgG2b, IgG3 with specific 
antibodies. Results showed that IgA, the most prevalent antibody at mucosal sites,
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decrease in AOM/DSS mice compared to controls (Figure 23 A), while the other 
immunoglobulins increase (Figure 23 B-E). This indicates a skewed
immunoglobulin repertoire during carcinogenesis and suggests that the presence 
of TLT associates to B cell maturation and isotype switch and the generation of a 
humoral immune response, possibly accounting for an antitumor function.
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Figure 23. Analysis of immunoglobulins in the stool of AOM/DSS mice.
Immunoglobulins have been quantified by ELISA using specific antibodies: anti- 
IgA, anti-IgM, anti-IgGl, anti-IgG2b, anti-IgG3. Stool IgA are more abundant in 
control mice compared to tumour-bearing mice (A), while IgM, IgGl, IgG2b, IgG3 
increase in AOM/DSS mice compared to controls (B-E). * p <0.05 by Student's T 
test
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Evaluation o f tumour growth and analysis o f the immune infiltrate in the 
CMT93 model
In the second preclinical model, I have subcutaneously injected both wt and pMT 
mice with a murine cell line of CRC, the CMT93 cell line. In contrast to the 
AOM/DSS model, B cells only distributed scattered in the tissue, while in none of 
the tumours analysed I could document occurrence of TLT (not shown), likely due 
to the fast growth of the tumour mass, compared to the AOM/DSS model. 
Consistent with the distinct pattern of B cell distribution observed, genetic B-cell 
deficiency oppositely affected tumour growth in the CMT93 preclinical model 
compared to the AOM/DSS. Both tumour incidence (Figure 24A) and growth 
(Figure 24B) of CMT93 cells was reduced in pMT mice compared to controls, thus 
suggesting that interspersed B220-TILs might have a pro-tumoural role.
WT [XWIT WT nMT
Figure 24. Evaluation of tumour growth in the CMT93 model. Quantification of 
tumour incidence and volume in the CMT93 preclinical model of CRC. Tumour 
incidence (A, n = 12 wt, n = 13 pMT) and volume (B, n = 5 wt, n = 6 pMT) is 
reduced in pMT mice compared to controls, p = 0.03 by Chi square (A); *** p < 
0.001 by Student's T test (B)
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Thus, consistent with our hypothesis of a different role of B cells depending on 
their localization in the tumour tissue (here modelled by the two different 
preclinical models), and also in accordance with our clinical data, B cells seem to 
sustain tumour growth in colorectal cancer, when infiltrating the 
microenvironment as interspersed B-TILs. To investigate how B cells could 
contribute to a protumour function, I asked whether they modulate the type of 
immune response. To this aim, I performed a characterization of the immune 
infiltrate in the CMT93 model. Flow cytometric analysis of whole colons from wild 
type and |aMT CMT93 tumours indicated a significant and selective increased 
infiltration of T lymphocytes, including CD8+ T cells as compared to tumours 
growing in wild-type mice (Figure 25).
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Figure 25. Analysis of the immune infiltrate in wt vs pMT CMT93-injected 
mice. There is a significant increase of T lymphocytes, including CD3 and CD8 + 
cells, in pMT mice compared to wt mice as shown in dot plots (A) and summarised 
in the histograms (wt: white bars; pMT: black bars; C). Panel B shows the 
infiltration of macrophages and neutrophils, which is significantly higher in wt 
mice compared to pMT mice (B), as summarised in panel C (C). *p < 0.05; ** 
p<0.01 by Student's T test
I then performed immunofluorescence stainings with anti-CD3 and anti-CD8 
antibodies on tumour sections and analysed samples by confocal microscope, 
confirming that there is an increase in tumour infiltrating CD3+T cells and CD8+T 
cells in mice lacking B cells (Figure 26 C-D) compared to tumour-bearing wt mice 
(Figure 26 A-B].
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Figure 26. Analysis of the immune infiltrate in CMT93 tumours. Frozen 
sections of CMT93 subcutaneous tumours in wt (upper panels) and pMT (lower 
panels) mice were stained with anti-CD3 (green, A-C) and anti-CD8 (red, B-D) 
antibodies. Tumours from mice lacking B cells have an increased infiltrate of 
immune cells, specifically CD3+T cells and CD8+T cells compared to wt tumour- 
bearing mice. Scale bars: 50 pm
Finally, I further analysed the type of immune response by evaluating the gene 
expression profile of CMT93 tumours. In particular, I tested genes related to the 
anti-tumour immune response, such as Granzyme, Perforin, TNF. I found that 
activated several genes, including IL-12, Granzyme A and B, Perforin, INF-gamma 
and TNF-alpha are highly expressed in pMT tumour-bearing mice compared to 
controls (Figure 27). These results suggest that, in an implanted tumour model 
devoid of B220-TLT, depletion of tumour infiltrating B cells (B-TILs) increase the 
recruitment of important components of the antitumour immune response.
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Figure 27. Gene expression profile in CMT93 tumours. Gene expression 
performed on RNA from CMT93-tumours, from both wt and pMT mice. There is a 
strong up-regulation of the genes related to the anti-tumour immune response in 
pMT mice (black columns] compared to wt mice (white columns]. Granzyme A, 
Granzyme B, IL-12, INF, TNF, CCR5 are significantly up regulated. * p < 0.05, *** p <
0.001 by Student's t test.
Preliminary analysis of CD20-TILs in human CRC
According to the data shown so far, B cells have a different influence on tumour 
growth, depending on their localization within the colon mucosa during 
tumorigenesis. My analysis of B-cell function in different preclinical models 
suggests a potential antitumour function for B cells when localized within TLT and 
a pro-tumour function of diffusely infiltrating B cells. As a preliminary explanation 
for this duality, I have provided evidence that B cells regulate the type of immune 
reaction in CRC, as their absence is associated to increased infiltration of important 
components of the antitumour immune response (Figure 25-27). Besides their 
primary role as antibody-producing cells, B cells can also release modulatory 
cytokines with important regulatory function [72]. IL-10-producing B cells have 
been recently implied in the restrain of excessive inflammation [163] and in cancer 
[76]. In addition, a population of PDL-1 expressing B cells has been described to be 
involved in immunosuppression in prostate cancer [73]. Thus, based on this 
literature and in order to preliminary investigate the mechanisms underpinning B- 
cell pro-tumour function in CRC, I focused on two key molecules with 
immunosuppressive function, IL-10 and PD-L1. By immunohistochemistry with 
specific antibodies against IL-10 and PD-L1 on human colorectal cancer specimens, 
I identified scattered CD20+ B cells expressing IL-10 (Figure 28 A), which, in 
contrast, was not expressed by B cells within TLT (Figure 28 B) and few CD20- 
TILs showing PD-L1 expression (Figure 28 C).
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Figure 28. CD20-TIL expression of im munosuppressive cytokines in human 
CRC. Expression of regulatory molecules by CD20-TILs. Immunohistochemistry 
with anti-IL-10 and CD20 (A-B). Some CD20-TILs show positivity for both IL-10 
(A), which is not expressed in B cells within TLT (B) and PD-L1 (C). Scale bars: 100 
pm.
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Discussion
In the second part of my thesis, I have presented data about the involvement of B 
cells in tumour progression in the microenvironment of CRC. Surprisingly, while T 
cell subsets occupy a prime position in studies aimed at assessing the role of 
leukocytes in cancer, cells of the humoural arm of the immune system have shown 
an unconvincing behaviour in most prognostic studies. Nonetheless, B and T cells 
are often localized in tight association into aggregates in the tumour 
microenvironment, possibly reflecting how they interact during the organization of 
a local immune response [92, 143]. In the first part of the results, focused on T 
cells, I showed that B cells represent a relevant component of TLT, both in humans 
and in mice. However, as for T cells, visualization of B cells in the 
microenvironment by immunohistochemistry revealed that B cells distribute in 
distinct regions at the tumour-host interface: they localised both in TLT in the 
stromal compartment (CD20-TLT) and scattered at the tumour margin (CD20- 
TILs). Despite whole tissue visualisation of CD20+B cells evidenced that they were 
preferentially located within TLT, instead of being diffuse within the tissue as TILs, 
the peculiar distribution in two distinct histo-pathological compartments 
prompted me to evaluate the role of B cells according to their localization. I found 
that CD20-TLT associated to better prognosis, while CD20-TILs did not. 
Interestingly, CD20-TLT coordinated with CD20-TILs only among patients who 
experienced cancer recurrence. This results suggests that, when located within a 
lymphoid site, B cells might be involved in an ongoing follicular anti-tumour 
immune response with a protective anti-tumour role. Conversely, the distribution 
of B cells scattered in the microenvironment is likely to reflect a non-specific pro­
tumour inflammatory reaction.
To partially explain the antitumour function of B cells within TLT, I explored 
whether TLT could be site for immune response, by analysing the immunoglobulin 
profile and two proliferation markers, representative of an ! active GC. Among 
tumour infiltrating B cells, very few or none were of the IgA subclass, recently
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associated to an immunosuppressive function in prostate cancer [73], while 
predominantly of the IgG subclass, suggesting a different antigenic response 
compared to normal colonic mucosa. Moreover, within TLT, I observed germinal 
centres, characterized by Ki-67+ proliferating cells and BCL6+ cells, suggesting 
that TLT have the potential to sustain switch recombination and somatic hyper 
mutation, which are required for the generation of an effector and memoiy B cell 
response. Overall, the profile of the B cell compartment of TLT suggests that this 
immune site is fully equipped to sustain B cell antibody production in human CRC, 
which can be crucial trigger of anticancer cellular immune responses [161].
I then took advantage of different CRC preclinical models, in order to dissect the 
role of the distinct B cell components (B-TILs and B-TLT}.
What I found is that, in a model in which B cells localize primarily within TLT and 
also spread in the tissue, the absence of B cells significantly increased tumour 
formation, suggesting that B cells within TLT might exert an important anti­
tumour function, which, according to my previous data, could be related to the 
capability of TLT to sustain a GC reaction. In contrast, in a model in which B cells 
only localize within the tissue, genetic ablation of B cells reduces tumour growth, 
suggesting that infiltrating B220-TILs might have a pro-tumour role, which could 
be related, according to my results, to inhibition of important components of the 
anti-tumour immune response. B-TILs could have a non-protective role, likely to 
be mediated by the production of immunosuppressive molecules, including IL-10 
and PDL-1. IL-10 positive B cells are B regulatory cells that contribute to the 
inhibition of excessive inflammation and support the immunological tolerance 
[72]. B reg cells are involved in the control of inflammation by IL-10 production in 
preclinical models of colitis [164], in EAE (Experimental Autoimmune 
Encephalomyelitis [83] and arthritis [165]. PD-L1 is expressed on many cancer and 
immune cells and plays an important role in blocking the anti-tumour immune 
response by binding PD-1, negative regulator of T-lymphocyte activation; it 
reduces cytokine production and supresses T cell proliferation [166]. Its 
expression on B cells could be important immunosuppressive signal when B cells 
are engaged in antigen-presenting functions.
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One interesting point that has emerged from my thesis is the importance of 
immuno-histo-pathological methodologies, carefully evaluating immune cells in 
the microenvironment. Gene-expression-based and FACS-based analyses are the 
most commonly used methods to address the prognostic role of immune cell 
populations. In the context of CRC, the localization and the structural organization 
of immune cells are key regulators of their function, as evidenced by my results. 
Overall, a new idea has emerged: the relevance of B cells in human cancer should 
take into account their localization with regard to lymphoid neo-genesis, which 
plays an important role in dictating their function in the tumour 
microenvironment.
The role of B cells in the progression of solid tumours has fostered studies 
concerning their targeting by anti-CD20 antibodies [162, 167-169]. In relation to 
the role I have found for CD20-TLT and CD20-TILs, respectively anti-tumour and 
pro-tumour, in the context of immunotherapy, I can speculate that targeting pro­
tumour CD20-TILs could be an effective immunotherapeutic tool against tumour 
progression, whereas depletion of CD20-TLT with anti-tumour properties might be 
counterintuitive in the clinical context of CRC. Thus, the effectiveness of anti-CD20 
treatment in solid tumours might be the result of its ability to selectively target 
interspersed CD20-TILs, while being less efficient in depleting B cells within TLT at 
the tumour margin. A considerable amount of studies showed that genetic 
inactivation of B cells induced tumour growth and unleashed adaptive immune 
cells [170, 171], while a previous study in an experimental tumour model argued 
against B cell depletion showing a higher tumour growth and impaired CD4+ and 
CD8+ T cell induction after anti-CD20 treatment [172]. Discrepancies between 
studies were explained by claiming developmental differences in the immune 
repertoire between genetic and late depletion of B cells. Thus, the effectiveness of 
anti-CD20 treatment in solid tumours that has been previously observed in both 
clinical [168] and experimental models [168] might be the result of its ability to 
selectively target interspersed CD20-TILs, while being less efficient in depleting B 
cells within TLT at the tumour margin. Design of novel immunotherapeutic drugs 
depleting B cells should take into account their ability to selectively targeting CD20 
TILs but not CD20-TLT. In this regard, the kinetic of B cell depletion by anti-CD20
antibodies varies among different B cell sub-populations (i.e. circulating, marginal 
zone, peritoneal] [173], thus suggesting that it's possible to preferentially target 
specific subsets. Moreover, in non-tumour conditions, anti-CD20 therapy has 
resulted ineffective in depleting CD20+ cells in tertiary lymphoid organs [174], 
suggesting that B cells might receive survival signals within lymphoid niches [173]. 
The differential sensitivity that B cells display to anti-CD20 treatment according to 
their localization could be exploited to design tailored approaches, assuming that a 
rigorous evaluation of B cell spatial distribution is performed.
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In my thesis I have examined the occurrence of TLT in the microenvironment of 
human CRC, the mechanisms driving its formation, its capability to mediate T cell 
recruitment and its relevance as a prognostic immune variable. In a second part, I 
have moved forward to examine the function of the humoral component of TLT, i.e. 
B cells, and explored the duality of these immune cells in relation to their spatial 
distribution in the microenvironment of human CRC. My data, overall, suggest that 
tertiary lymphoid tissue is a relatively novel component of the immune 
microenvironment of colorectal cancer with a key role as prognostic tool and in 
the design of novel immunotherapeutic strategies.
The tumour microenvironment is the site where host and cancer cells interact. 
Within the tumour microenvironment, tumour complexity is due not only to the 
intrinsic heterogeneity of cancer cells, but also to the variety of tumour infiltrating 
immune cells. The anti-tumour function of adaptive immune cells is target of 
immunotherapeutic strategies, aiming at stimulate the anti-tumour immune 
response. At the same time, immunosuppressive circuits are targets of therapeutic 
approaches aimed at reverting the exhausted immune landscape and boosting an 
effective immune response. Research in tumour immunology is thus strengthening 
the knowledge of the mechanisms driving the action of immune cells in the tumour 
context, with the ultimate goal to provide new diagnostic, therapeutic and 
prognostic tools to the clinical practice [33, 87]. However, the clinical 
characterization of tumour infdtrating cells needs to be ameliorated, in order to 
identify ideal targets of effective therapeutic strategies.
In the last decades, tumour profiles generated by standardized wide-scale analyses 
have highlighted a central position of immune variables in dictating tumour 
progression [93,175], suggesting that specific immune subsets should be included 
within the currently available TNM staging system in the determination of 
patient's prognosis [61]. Thus, cancer research is constantly engaged in the 
identification of the specific immune profile of each solid tumour. Overall, these 
studies highlight that effector T cells in the tumour environment correlate with a 
better tumour prognosis [35, 94, 176]. Inflammatory mediators are undoubtedly
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involved in CRC initiation as well as progression. However, CRC is a tumour where 
most consistently tumour-infiltrating T cells have been demonstrated to have a 
protective role, being significantly associated with better clinical outcome [60, 61].
Despite the presence of effector T cells in solid tumours correlates with a 
favourable prognosis in the majority of tumour types, the mechanisms of T cell 
recruitment and activation largely remain to be defined. In a physiologic context, 
immune responses are generated within lymphoid organs thanks to specific 
cellular and molecular interactions. Anti-tumour T cells get activated in SLO, after 
tumour-antigen retrieval by DCs in the inflamed microenvironment [177, 178], 
Once activated, T cells migrate to the tumour, where they exert their anti-tumour 
function against tumour-antigen expressing cells. Lately, it has been shown that, 
occasionally, adaptive immune responses and priming of naive T cells could arise 
in ectopic lymphoid sites in peripheral tissues. TLT has been well characterized as 
an ectopic immunological compartment with a highly organized structure. It 
mediates lymphocyte recruitment from the blood and it could give a contribution 
to the generation of adaptive immune responses [92, 145, 176], thanks to 
topological compartmentalization, the presence of stromal cells and a specialized 
vessel network.
It is now established that TILs have a positive prognostic role in solid tumours,
reflecting the potential ability of adaptive immune cells to exert tumour control.
Recently, the approach to investigate the relevance of TILs in human cancer has
been improved: the analysis of adaptive cells is combined with the definition of
specific subsets and their quantitative distribution in the tumour
microenvironment. Despite the advent of innovative prognostic tools, such as
global molecular analyses, histopathological examination of immune cells in
tumours still stands as one of the most powerful approaches to assess the
relevance of the complex immune microenvironment. It's only thanks to careful
histopathological examination of immune variables within the microenvironment
that it has been possible to appreciate the spatial organization of immune cells as
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an important determinant of immune cell function and a critical feature in 
establishing patient outcome [52,144].
In 1967, pathologists, analysing haematoxylin and eosin (H&E)- stained tumour 
tissue slides, found that an unspecific lymphocytic "inflammatory reaction" could 
represent a prognostic feature, although devoid of information on specific 
subpopulations of immune cells [179]. Now a day, it is possible to create a 
reproducible immune signature in definite tumour locations, for example at the 
invasive margin, thanks to both the development of immunohistochemistry-based 
methodologies for the detection of specific lymphocyte surface markers and 
computer-based quantitative image analysis. This binomial makes possible an 
accurate assessment of the prognostic role of TIL subsets
Cancer immunotherapy is known as a group of strategies which their purpose is to 
activate immune mechanisms or neutralise inhibitory and suppressing immune 
networks. Among innovative immunotherapeutic strategies, those aiming at 
increase the extent of TILs in tumour microenvironment are supported by the 
prognostic relevance of TILs. Recently, thanks to preclinical and clinical studies, 
TLT has become a critical player in this model, since it sustains the recruitment 
and activation of immune cells to the tumour microenvironment. One of the limit 
in the success of immunotherapeutic approaches is the homing of anti-tumour T 
cells to the tumour. In this scenario, the development of TLT in the tumour 
microenvironment could represent an useful instrument that facilitates the 
recruitment of effector T cells in those areas barely accessible. Moreover, the 
detection of TLT at the tumour site during immunotherapy might be a monitoring 
strategy useful in identifying patients who are prone to respond to 
immunotherapy strategies aimed at boosting the host immune response. Lutz et al 
demonstrated that TLT was induced in 33 out of 39 pancreatic cancer patients 
enrolled in a clinical trial [180]. The core of the study consisted in an irradiated 
granulocyte colony stimulating factor (GM-CSF]-secreting allogeneic pancreatic 
cancer vaccine (GVAX). With this trial, it has been demonstrated that TLT can be
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targeted by immunotherapy to orchestrate T cell infiltration and participate in the 
generation of an immunogenic environment [180].
Due to their ability to activate lymphocytes, DCs might represent a central actor in 
immunotherapy. Accordingly, it has been shown that activated DCs can sustain the 
formation of organized lymphoid tissue in preclinical models [181, 182]. Data 
reported are supported by the presence of DCs in lymphoid organs and their 
pivotal role in the initial aggregation of lymphocytes during lymphorganogenesis 
and in vessel formation. However, most of clinical trials with DC-based 
immunotherapy stopped at phase II.
B and T cells are often localized in tight association into aggregates in the tumour 
microenvironment, possibly reflecting how they interact during the organization of 
a local immune response [54, 92,152,183]. In my study, I have documented that B 
cells in human CRC localized both in tertiary lymphoid tissue in the stromal 
compartment [CD20-TLT] and scattered around the tumour margin (CD20-TILs). 
B cells within tertiary lymphoid structures were shown to be antigen specific and 
to correlate to favourable prognosis in NSCLC [54]. In our analysis, CD20-TLT 
associated to better prognosis, suggesting that, when localized within a lymphoid 
site, B cells might be involved in an ongoing follicular antitumor immune response 
with a protective antitumor role. Differently, B cells scattered in the tumour tissue 
were not associated with better prognosis and notably CD20-TLT coordinated with 
B cells only among patients who experienced cancer recurrence. Thus, it is 
tentative to speculate that while the recruitment of scattered B cells is likely to 
reflect a non-specific pro-tumour inflammatory reaction, the presence of B cells as 
a component of lymphoid aggregates mirrors an antigen-driven expansion with a 
potential protective antitumor role. Our analysis highlights the importance of B 
cell distribution in predicting colorectal cancer prognosis and raises criticism 
about studies addressing the prognostic role of B cell signatures obtained by gene 
expression-based or FACS-based analyses, due to the unspecific quantification of B 
cells with regard to their localization in the tumour microenvironment [184] and 
highlight the importance of immunohistopathological methodologies in this
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context. Our study brought to light the idea that the relevance of B cells in human 
cancer should take into account of their localization and geographical distribution 
with regard to lymphoid neogenesis, which plays an important role in dictating 
their function in the tumour microenvironment.
In the context of novel immunotherapy treatments, our data propose that targeting 
pro-tumour CD20-TILs could be an effective immunotherapeutic tool against 
tumour progression, whereas depletion of CD20-TLT with anti-tumour properties 
might be counterintuitive in the clinical context of CRC. Our study suggest that 
novel immunotherapies strategies aimed at depleting B cells in solid tumours 
[185] should be tested for their anti-tumour properties in experimental models 
according to their ability to generate the de-novo formation of TLT in the tumour 
microenvironment.
The design of novel immunotherapeutic strategies able to increase lymphocyte 
recruitment and activation at the tumour site is supported by the prognostic 
abilities of TILs. In this context, a new central actor has been proposed in the 
classification of patient survival: the presence of TLT in the tumour 
microenvironment. If TLT is an active and functional immune site that participate 
in the recruitment and activation of T cells in the tumour microenvironment, as 
experimental and clinical studies report, then immunotherapeutic approaches 
could exploit the occurrence of TLT to increase the delivery of effective T cells to 
otherwise unreachable tumour areas.
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LIST OF ABBREVIATIONS
CRC Colorectal cancer
TIL Tumour infiltrating lymphocytes
TLT Tertiary lymphoid tissue
HEV High endothelial venules
GFP Green fluorescent protein
WHO World health organisation
IBD Inflammatory bowel disease
HNCCP Hereditary non polyposis colorectal cancer
FAP Familiar adenomatous polyposis
MLH1 MutL homolog 1
MSH2 MutS homolog 2
APC Adenomatous Polyposis Coli
CIN Chromosomal instability
MSI Microsatellite instability
TNM Tumour Node Metastasis
EGFR Epidermal growth factor receptor
MMR Mismatch repair
mAbs Monoclonal antibodies
VEGF Vascular endothelial growth factor
PD1 Programmed cell death-1
PDL1 Programmed cell death-1 ligand
CAC Colitis-associated colorectal cancer
MDSC Myeloid-derived suppressor cells
NK Natural killer
DC Dendritic cells
VELIPI Vascular emboli, lymphatic invasion and perineural invasion
Thl T helper 1
Breg B regulatory cell
IL-10 Interleukin 10
TGF-p Transforming growth factor beta
APC Antigen-presenting cells
CT Centre of the tumour
IM Invasive margin
DFS Disease free survival
DSS Disease specific survival
OS Overall survival
MALT Mucosal associated lymphoid tissue
GALT Gut-associated lymphoid tissue
IEL Intra-epithelial lymphocytes
LPL Lamina propria leukocytes
PP Peyer's Patch
IgA Immunoglobulin A
IgG Immunoglobulin G
MLN Mesenteric Lymph Nodes
CP Criptopatch
ILF Isolated lymphoid follicles
LTi Lymphoid tissue inducer
SCF-R Stem cell factor receptor
IL-7R Interleukin 7 receptor
CSR Class Switching Recombination
SLO Secondary lymphoid organ
GC Germinal Centre
ELS Ectopic lymphoid-like structures
FRCs Follicular reticular cells
FDC Follicular dendritic cells
TNF Tumour necrosis factor
LTo Lymphoid tissue organizer
LTi Lymphoid tissue inducer
LTpR Lymphotoxin beta receptor
LTCC1P2 Lymphotoxin alpha 1 beta 2
ACPA Anti-citrullinated protein antibodies
HP Helicobacter pylori
IDC Infiltrating ductal carcinoma
TI-BALT Tumour Induced -  Bronchus-Associated Lymphoid Tissue 
NSCLC Non-small-cell lung cancer (NSCLC)
AOM Azoxymethane
DSS Dextran sulphate sodium
ApcMin Adenomatous Polyposis Coli - Multiple intestinal neoplasia
IRA Immune reactive area
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